Document:

Blueprint

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

AMENDED AND RESTATED LICENSE AGREEMENT

 

THIS
AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”), effective as
of September 24, 2014 (the “Effective Date”), is
entered into between Tactic Pharma, LLC, a limited liability
company (“TACTIC”), having offices
at 1062 Princeton Avenue, Highland Park, IL 60035 and XOMA (US)
LLC, a Delaware limited liability company (“XOMA”), having offices at
2910 Seventh Street, Berkeley, California 94710. Each of XOMA and
TACTIC are sometimes referred to herein separately as a
“Party”
and together as “Parties.”

 

WHEREAS
TACTIC was formed upon the dissolution of Attenuon, LLC, San Diego,
California, 92121 (“ATTENUON”), such that TACTIC can be
considered a successor of ATTENUON;

 

WHEREAS
TACTIC is the successor and rightful owner of certain IP rights
developed by ATTENUON, including, but not limited to,
ATN-658;

 

WHEREAS
ATTENUON and XOMA had entered into a certain HUMAN
ENGINEERINGTM LICENSE AGREEMENT, effective September 29, 2006,
(the “Prior Agreement”) in which, among other things,
Attenuon, LLC obtained a license to certain HUMAN ENGINEERING
PATENT RIGHTS as described in the Prior Agreement for the purposes
of developing and commercializing human engineered
ATN-658;

 

WHEREAS
for the good and valuable consideration set forth in this
agreement, the Parties agree that all rights, claims, and
obligations under the Prior Agreement between Attenuon, LLC, its
successors, and XOMA are now null and void unless expressly
restated herein. Accordingly, the Parties agree that there are no
outstanding payments, liabilities, or other obligations owed by
TACTIC to XOMA under the Prior Agreement.

 

For
good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties agree as
follows:

 

ARTICLE
1

 

 

 

DEFINITIONS

 

For
purposes of this Agreement, the terms defined in this Article 1
shall have the respective meanings set forth below:

 

1.1 “Affiliate” shall mean,
with respect to any Person, any other Person which, presently or in
the future, directly or indirectly controls, is controlled by, or
is under common control with, such Person.

 

1.2 “Antibody” shall mean any
immunoglobulin molecule (such as IgG), whether in monospecific or
any other form, and shall include, without limitation, any
immunoglobulin fragment (such as Fv, Fab, F(ab') or
F(ab')2),
any fusion protein of an immunoglobulin or immunoglobulin fragment
and any single chain antibody (such as scFv), as well as any
derivative of any of the foregoing.

 

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

1.3 “TACTIC Antibody” shall
mean the non-human Antibody directed to the TACTIC Target, referred
to by TACTIC as “ATN-658”

 

1.4  “TACTIC
Patent Rights” shall have the meaning set forth in
Section 1.6.

 

1.5 “TACTIC Program
Inventions” shall have the meaning set forth in
Section 1.6.

 

1.6  “TACTIC
Program Inventions and Patent Rights” shall mean any
and all (a) Program Inventions, whether or not patentable, that (i)
comprise or embody (A) [***], (B) [***], (C) [***], (D) [***], (E)
[***] and (F) any uses of any and all of the foregoing, or (ii) do
not meet the definition of [***] by virtue of the preceding clause
(i) or the definition of [***] by virtue of clause (i) thereof and
were [***] (collectively, the “TACTIC Program
Inventions”); and (b) Patent Rights arising out of the
conduct of activities under the Prior Agreement that claim or cover
such TACTIC Program Inventions (the “TACTIC Patent Rights”).
Notwithstanding the foregoing, TACTIC Program Inventions and Patent
Rights do not include any [***] and Patent Rights; provided that the foregoing shall not
apply to [***] (I) [***] (II) [***] (III) [***] (IV) [***] (V)
[***] and (VI) any uses of any and all of the foregoing, each of
which shall be included in the [***] and [***].

 

1.7 “TACTIC Target” shall mean
the target antigen known as urokinase-type plasminogen activator
receptor (uPAR).

 

1.8 “Combination Product”
shall have the meaning set forth in Section 1.22.

 

1.9 “Composition of Matter”
shall mean any composition of matter or article of
manufacture.

 

1.10 “Confidential
Information” shall mean any proprietary or
confidential information or material disclosed by a Party to the
other Party pursuant to the Prior Agreement or this Agreement which
is (a) disclosed in tangible form and is designated thereon as
“Confidential” at the time it is delivered to the
receiving Party, or (b) disclosed orally and identified as
confidential or proprietary when disclosed and such disclosure of
confidential information is confirmed in writing within thirty (30)
days by the disclosing Party. Notwithstanding the foregoing,
Confidential Information shall not include information which the
receiving Party can establish by written documentation (i) to have
been publicly known prior to disclosure of such information by the
disclosing Party to the receiving Party, (ii) to have become
publicly known, without fault on the part of the receiving Party,
subsequent to disclosure of such information by the disclosing
Party to the receiving Party, (iii) to have been received by the
receiving Party at any time from a source, other than the
disclosing Party, rightfully having possession of and the right to
disclose such information, other than under an obligation
of

 

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

confidentiality,
(iv) to have been otherwise rightfully known by the receiving Party
prior to disclosure of such information by the disclosing Party to
the receiving Party, other than under an obligation of
confidentiality, or (v) to have been independently developed by
employees or agents of the receiving Party without access to or use
of such information disclosed by the disclosing Party to the
receiving Party without violating any obligation of confidentiality
or non-use.

 

1.11 “Control,”
“Controls” and
“Controlled” shall mean,
with respect to a particular item of information or Intellectual
Property Right, that the applicable Party or any of its Affiliates
owns (whether solely or jointly with the other Party or any Third
Party), or has a license to, such item or right and has the ability
to grant to the other Party access to, and a license or sublicense
(as applicable) under, such item or right as provided for herein
without violating the terms of any agreement with any Third
Party.

 

1.12  “CPR”
shall have the meaning set forth in Section 9.2.

 

1.13 “Dispute”
shall have the meaning set forth in Section 9.1.

 

1.14 “Human
EngineerTM,” “Human EngineeredTM”
and “Human
EngineeringTM” shall mean, for purposes of this
Agreement, with respect to a particular Antibody, resulting from,
or otherwise practicing, the methods of the Human
EngineeringTM Patent Rights or any other proprietary protein
engineering methods used by XOMA for modifying non-human Antibodies
with the intended purpose of making them suitable for medical
purposes in humans.

 

1.15 “Human
EngineeredTM TACTIC Antibodies” shall mean the
Human EngineeredTM versions of the TACTIC Antibodies provided
by XOMA under the Prior Agreement.

 

1.16 “Human
EngineeringTM Patent Rights” shall mean the
Patent Rights listed on Schedule 1.16 hereto and all
patents issuing on any of the applications so listed, including
extensions, reissues and re-examinations.

 

1.17 “Indemnitee”
shall have the meaning set forth in Section 8.2.

 

1.18 “Indemnitor”
shall have the meaning set forth in Section 8.2.

 

1.19 “Intellectual
Property Rights” shall mean Patent Rights, copyrights,
trademarks, service marks, know-how, trade secrets, and
applications and registrations for the foregoing, in any country,
supranational organization or territory of the world.

 

1.20  "Joint
Program Inventions" shall mean
any and all Program Inventions, whether or not patentable, that are
invented jointly by employees, agents, consultants or contractors
of both [***], but [***].

 

1.21 "Major
Market Country" shall mean any of the United States of
America, Japan or any of the top five (5) countries (measured by
pharmaceutical sales for the most recently com­ pleted
calendar year for which such information is available at the time
of determination) of the European Union.

 

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

1.22  “Milestone
Payment” shall have the meaning set forth in Section
3.1.

 

1.23 “Net
Sales” shall mean the gross amount invoiced by TACTIC,
its Affiliates, assignees or sublicensees for sales of Products to
Third Parties, less
the following items, as allocable to such Products:

 

(a) trade discounts,
rebates or allowances actually allowed and taken directly with
respect to such sales;

 

(b) credits or
allowances additionally granted upon returns, rejections, recalls
or retroactive price reductions;

 

(c) freight, shipping
and insurance charges;

 

(d)
[***];

 

(e) taxes, duties or
other governmental tariffs (other than income taxes);
and

 

(f) government mandated
rebates.

 

In the
event that a Product is sold as part of a Combination Product (as
defined below) in any country, the Net Sales of the Product as part
of a Combination Product in that country for the purposes of
determining royalty payments shall be determined by multiplying the
Net Sales of the Combination Product in that country by the
fraction (A/A+B) where A is the average sale price in the relevant
quarterly period of the Product in that country when sold
separately in finished form and B is the average sale price in the
relevant quarterly period of the Other Element (as defined below)
in that country sold separately in finished form. In the event that
the average sale price of the Product in that country can be
determined but the average sale price of the Other Element in that
country cannot be determined, Net Sales of the Product in that
country for the purposes of determining royalty payments shall be
calculated by multiplying the Net Sales of the Combination Product
in that country by the fraction (C/D) where C is the selling
Party's average sales price in the relevant quarterly period of the
Product and D is the average selling price in the relevant
quarterly period of the Combination Product in that country. If the
average sale price of the Other Element in that quarterly period
can be determined but the average price of the Product in that
country cannot be determined, Net Sales of the Combination Product
in that country for the purposes of determining royalty payments
shall be calculated by multiplying the Net Sales of the Combination
Product in that country by the following formula: one (1) minus E/D where E is the average
selling price in the relevant quarterly period of the Other Element
in that country and D is the average selling price of the
Combination Product in that country in the relevant quarterly
period. If the average sale price of both the Product and the Other
Element cannot be deter­ mined, the Net Sales of the Product
shall be reasonably agreed upon by the Parties. As used herein, the
term "Combination
Product" shall mean a product which contains or comprises a
Product as an active component and at least one other active
compound (an "Other
Element").

 

 

Provision
of Products free of charge for clinical trials, for promotional or
sampling purposes or as donations (for example to non-profit
institutions or government agencies for a non-commercial purpose)
at levels not in excess of industry norms, shall not be considered
in determining Net Sales.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

1.24 “Patent
Prosecution” shall mean, with respect to particular
Patent Rights, (a) preparing, filing and prosecuting patent
applications (including, but not limited to, provisional,
non-provisional, reissue, reexamination, continuing, continuation,
continuation-in-part, divisional, and substitute applications and
any foreign counterparts thereof) of such Patent Rights; (b)
maintaining such Patent Rights; and (c) managing or conducting any
interference or opposition or similar proceedings relating to the
foregoing.

 

1.25 “Patent
Rights” shall mean any of the following, whether
existing now or in the future anywhere in the world:
(a) patents and patent applications; (b) continuations,
continuations-in-part, divisionals and substitute applications with
respect to any such patent application; (c) any patents issued
based on or claiming priority to any such patent applications;
(d) any reissue, reexamination, renewal or extension
(including any supplemental patent certificate) of any such
patents; and (e) any confirmation patent or registration patent or
patent of addition based on any such patents.

 

1.26 “Person”
shall mean an individual, corporation, partnership, limited
liability company, trust, business trust, association, joint stock
company, joint venture, pool, syndicate, sole proprietorship,
unincorporated organization, governmental authority or any other
form of entity or organization not specifically listed
herein.

 

1.27 “Product”
shall mean any Composition of Matter
that comprises or contains the Human EngineeredTM
Tactic Antibodies or any derivatives,
conjugates and/or fragments thereof.

 

1.28 "Program
Invention" shall mean any invention (whether or not
patentable), discovery, Composition of Matter, improvement,
enhancement, technology, data or information made or conceived in
connection with the conduct of activities pursuant to the Prior
Agreement.

 

1.29 “PTO”
shall have the meaning set forth in Section 5.4(c).

 

1.30 “Term”
shall have the meaning set forth in Section 7.1.

 

1.31 “Third
Party” shall mean any Person other than XOMA or TACTIC
or their Affiliates.

 

1.32 “Title
XI” shall have the meaning set forth in Section
11.2.

 

1.33  “Valid
Claim” shall mean (a) a claim of an issued and
unexpired patent which has not been held permanently revoked,
unenforceable or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal and that is not
admitted to be invalid or unenforceable through reissue, disclaimer
or otherwise, or (b) a claim (including amendments) of a pending
patent application that has neither (i) been abandoned or finally
rejected without the possibility of appeal or refiling nor (ii)
been pending for more than [***], provided that any claim excluded from
this definition in reliance on this clause (b)(ii) that
subsequently issues shall constitute a Valid Claim so long as it
meets the requirements of clause (a) above.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

1.34 "XOMA
Deliverables" shall mean the XOMA materials and information
delivered to ATTENUON under the Prior Agreement.

 

1.35 “XOMA
Patent Rights” shall have the meaning set forth in
Section 1.37.

 

1.36 “XOMA
Program Inventions” shall have the meaning set forth
in Section 1.37.

 

1.37 “XOMA
Program Inventions and Patent Rights” shall mean any
and all (a) Program Inventions, whether or not patentable, that (i)
comprise or embody (A) [***] (B) methods that are generally
applicable to the [***] or (ii) do not [***] and were invented
solely by employees, agents, consultants or contractors of [***]
(collectively, the “XOMA Program
Inventions”); and (b) all Patent Rights arising out of
the conduct of activities under the Prior Agreement that claim or
cover such XOMA Program Inventions (the “XOMA Patent
Rights”).

 

ARTICLE
2

 

 

 

INTELLECTUAL PROPERTY RIGHTS

 

2.1 License Grants to TACTIC. XOMA
hereby grants to TACTIC:

 

(a) a worldwide,
non-exclusive license, with the right to sublicense in its sole
discretion, under any and all Intellectual Property Rights
Controlled by XOMA at any time during the Term covering, claiming
or relating to Program Inventions, and/or XOMA’s Human
EngineeringTM technology utilized in XOMA's performance of work under the
Prior Agreement including, without limitation, the Human
EngineeringTM Patent
Rights), to make, have made, use, offer for sale, sell and import
Human EngineeredTM TACTIC Antibodies and any
Product.

 

2.2 Ownership of Intellectual
Property.

 

2.2.1 Inventorship
for Program Inventions shall be determined in accordance with U.S.
patent laws.

 

2.2.2 TACTIC
reserves and shall retain all right, title and interest in and to
the TACTIC Antibody and all Intellectual Property Rights
therein.

 

2.2.3 Subject
to the rights and licenses granted under this Agreement, ownership
of all Program Inventions, irrespective of inventorship, shall be
as follows: (a) TACTIC shall own TACTIC Program Inventions and
Patent Rights; (b) XOMA shall own all XOMA Program Inventions and
Patent Rights; and (c) TACTIC and
XOMA shall jointly own, in equal undivided shares, any Joint
Program Inventions.

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

2.2.4 XOMA
hereby assigns, and agrees to assign, to TACTIC all of XOMA’s
right, title and interest in and to any and all TACTIC Program
Inventions and Patent Rights, including, without limitation, the
right to sue for past, present and future infringement. XOMA
agrees, without further consideration, to execute all documents,
certificates and other instruments, and to do all acts reasonably
necessary to vest and confirm in TACTIC, its successors and
assigns, the legal title to all such Program Inventions and Patent
Rights; provided that, if
such requests require more than de
minimis out-of-pocket expenditures by XOMA, TACTIC will
reimburse XOMA for such expenditures, to the extent previously
approved by TACTIC in writing (which approval shall not be
unreasonably withheld or delayed).

 

2.2.5 TACTIC
hereby assigns, and agrees to assign, to XOMA all of TACTIC’s
right, title and interest in and to any and all XOMA Program
Inventions and Patent Rights, including, without limitation, the
right to sue for past, present and future infringement. TACTIC
agrees, without further consideration, to execute all documents,
certificates and other instruments, and to do all acts reasonably
necessary to vest and confirm in XOMA, its successors and assigns,
the legal title to all such Program Inventions and Patent Rights;
provided that, if such
requests require more than de
minimis out-of-pocket expenditures by TACTIC, XOMA will
reimburse TACTIC for such expenditures, to the extent previously
approved by XOMA in writing (which approval shall not be
unreasonably withheld or delayed).

 

2.3 No Implied Rights. Only the
rights and licenses granted pursuant to the express terms of this
Agreement shall be of any legal force. Without limiting the
foregoing and subject to the license granted by XOMA in Section
2.1, neither the grants provided in Section 2.1 nor the assignment
from XOMA to TACTIC provided in Section 2.2.4 provide TACTIC with
any right to practice the methods of the Human EngineeringTM
technology (including, without limitation, the Human
EngineeringTM Patent Rights)
or, subject to the grants made in Section 2.1, to receive from XOMA
or use information received from XOMA related to its Human
EngineeringTM technology, and in no event shall XOMA be
required to disclose such methods or information.

 

2.4 Sublicenses. Any sublicense
permitted hereunder shall be set forth in a written agreement
containing provisions relating to ownership of intellectual
property that are substantially consistent with, and with respect
to audits and confidentiality that are substantially consistent
with, and at least as stringent as, those contained herein and
shall be subject and subordinate to the terms and conditions of
this Agreement.

 

ARTICLE
3

 

 

 

FINANCIAL TERMS

 

3.1 Milestone Payments. In full
consideration of the rights and licenses granted to TACTIC herein,
TACTIC shall pay to XOMA the applicable payments below (each, a
“Milestone
Payment”)

 

	

Event

 

	

Payment

 

	

1.
[***]

 

	

[***]

 

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

	

2.
[***]

 

	

[***]

 

	

3.
[***]

 

	

[***]

 

	

4.
[***]

 

	

[***]

 

	

5.
[***]

 

	

[***]

 

	

6.
[***]

 

	

[***]

 

Each
Milestone Payment shall be due [***] days from the achievement of
the corresponding milestone event. Each Milestone Payment [***],
and [***] (a) [***] or (b) [***].

 

3.2 Third Party Payments. TACTIC
will be responsible for all financial obligations due Third
Parties.

 

3.3 Payments; Currency. All
payments due under this Article 3 shall be paid in United States
dollars in immediately available funds to an account designated by
XOMA.

 

3.4 Payment Reports and
Timing.

 

3.4.1 TACTIC
shall make a written report to XOMA within thirty (30) days of the
achievement of each of the milestones set forth in Section 3.1
with respect to Product

 

3.5 Payment Records and
Audits.

 

3.5.1 TACTIC
shall, and shall contractually require all Third Parties selling
Products on its behalf to, keep complete and accurate books of
account for, and records of Net Sales of, Product in sufficient
detail to enable the milestone payments payable under this
Agreement to be determined

 

3.5.2 Upon
the written request of XOMA, TACTIC shall permit an independent
auditor appointed by XOMA and reasonably acceptable to TACTIC to
have access during normal business hours to such of the records of
TACTIC and its Affiliates as may be reasonably necessary to verify
the accuracy of the Net Sales under this Agreement. The auditor
shall only disclose to XOMA whether the Net Sales reported are
correct or incorrect and the amount of any discrepancy. No other
information shall be provided to XOMA without the prior consent of
TACTIC unless disclosure is required by law, regulation or judicial
order. If XOMA determines that disclosure is required by law,
regulation or judicial order, it shall give TACTIC reasonable prior
notice thereof in order for TACTIC to seek a protective order
against or limiting such disclosure. TACTIC is entitled to require
the auditor to execute a reasonable confidentiality agreement prior
to commencing any such audit. Any agreement between TACTIC and/or
any of its Affiliates, on the one hand, and one or more Third
Parties, on the other hand, pursuant to which such Third Party may
market and/or sell Product shall contain provisions for access and
inspection of records substantially similar to the
foregoing.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

3.5.3 Audits
conducted under this Section 3.5 shall be at the expense of XOMA
unless an unpaid amount for the full
period covered by the audit is identified, in which case all
reasonable out-of-pocket costs incurred by the auditor to perform
the audit will be paid promptly by TACTIC. Any unpaid amounts
discovered by such inspections or otherwise will be paid promptly
by TACTIC, with interest on such amounts from the date(s) such
amount(s) were due, at a rate equal to the lesser of the prime rate
reported by the Bank of America plus [***] per annum, or the
highest interest rate permitted under applicable New York
law.

 

ARTICLE
4

 

 

 

CONFIDENTIALITY

 

4.1 Confidential Information.
Except as expressly provided herein, the Parties agree that, for
the Term and for [***] thereafter, each of them shall keep
completely confidential and shall not publish or otherwise disclose
and shall not use for any purpose except for the purposes
contemplated by this Agreement any Confidential Information
furnished to it by the other Party. Each Party also agrees to cause
its Affiliates with access to any Confidential Information to
comply with all terms of this Agreement relating to such
Confidential Information and the treatment thereof, and each Party
shall remain primarily liable for any breach of any such provision
by any of its Affiliates.

 

4.2 Permitted Use and Disclosures.
The receiving Party may use or disclose Confidential Information to
the extent such use or disclosure is reasonably necessary in
complying with any applicable law, regulation or court order or in
conducting clinical trials or in connection with seeking, enforcing
or defending Patent Rights covering Program Inventions;
provided that if the
receiving Party is required to make any such disclosure of
Confidential Information, other than pursuant to a confidentiality
agreement, it will give reasonable advance notice to the disclosing
Party of such disclosure and will use its reasonable efforts to
secure confidential treatment of such Confidential Information
prior to its disclosure (whether through protective orders or
otherwise). Notwithstanding the foregoing, TACTIC may use and
disclose the Confidential Information of XOMA as reasonably
necessary in connection with the exercise of TACTIC’s rights
under Section 2.1(a) and otherwise with respect to the development
or exploitation of TACTIC Program Inventions and Patent Rights,
including, without limitation, to actual or prospective business
partners, investors, contractors, and sublicensees of TACTIC, in
each case, pursuant to a confidentiality agreement with terms
substantially consistent with, and at least as stringent as, those
set forth in this Agreement.

 

4.3 Confidential
Terms. Except as expressly
provided herein, each Party agrees not to disclose any terms of
this Agreement to any Third Party without the consent of the other
Party; provided
that disclosures may be made as
required by securities or other applicable laws, or as reasonably
necessary to actual or prospective business partners, investors and
Tactic's sublicensees under this Agreement pursuant to a
confidentiality agreement with terms at least as stringent as those
in this Agreement, or to a Party's accountants, attorneys and other
professional advisors owing a contractual or other duty of
confidentiality to such Party. Upon the reasonable written request
of the disclosing Party, the receiving Party shall promptly return
or destroy, and certify the same in writing, all Confidential
Information of the other Party; provided that the receiving Party may retain one (1) copy
of any such Confidential Information in its files for purposes of
maintaining appropriate records of its activities in connection
with this Agreement.

 

 

 

4.4 Use of Name. Neither Party
shall use the name or trademarks of the other Party, except to the
extent that a Party is permitted to use the Confidential
Information of the other Party or required to do so pursuant to
this Article 4, without the prior written consent of such other
Party, such consent not to be unreasonably withheld or
delayed.

 

4.5 Previous Agreements. The
parties acknowledge and understand that the Prior Agreement is now
void and superseded by this Agreement.

 

ARTICLE
5

 

 

 

PATENT RIGHTS

 

5.1 Prosecution and Maintenance of TACTIC
and XOMA Patent Rights. TACTIC shall have sole and exclusive
responsibility for Patent Prosecution of all TACTIC Patent Rights.
XOMA shall have sole and exclusive responsibility for Patent
Prosecution of XOMA Patent Rights. In each such case, the
non-prosecuting Party will provide the prosecuting Party with such
assistance and execute such documents as are reasonably necessary
to permit or continue such Patent Prosecution by the prosecuting
Party. The prosecuting Party shall bear all Patent Prosecution
expenses, including attorneys’ fees, incurred by such Party,
or by the other Party at the request of the prosecuting Party, in
the performance of Patent Prosecution.

 

5.2 Enforcement of TACTIC and XOMA Patent
Rights.

 

5.2.1                      Notifications.
Each Party shall provide to the other Party copies of (a) any
written notices it receives from any Third Party regarding any
patent nullity action, declaratory judgment action, alleged
invalidity, unenforceability, infringement or non-infringement with
respect to or alleged misappropriation of intellectual property
with respect to Program Inventions, or the TACTIC Patent Rights,
and (b) any written allegations it receives from a Third Party that
the manufacture, use, sale, offer for sale or import of Product
infringes the Intellectual Property Rights of such Third Party, in
each case promptly following receipt thereof.

 

5.2.2                      Infringement
Proceedings Against Third Parties. TACTIC shall have the
sole and exclusive right, but not the obligation, to institute and
direct legal proceedings against any Third Party believed to be
infringing the TACTIC Patent Rights. XOMA shall have the sole and
exclusive right, but not the obligation, to institute and direct
legal proceedings against any Third Party believed to be infringing
any XOMA Patent Rights. Each Party will bear all of its own costs,
including attorneys’ fees, relating to such legal
proceedings; provided that
the Party directing such legal proceedings shall bear the other
Party’s out-of-pocket expenses, including attorneys’
fees, incurred in complying with requests for cooperation made by
the directing Party. Without limiting the foregoing, any recovery
in connection with such suit or proceeding will be retained solely
by the Party directing such suit or proceeding.

 

 

 

5.3 Infringement Proceedings by Third
Parties. In the event that a Party receives written notice
that it or any of its Affiliates have been individually named as a
defendant in a legal proceeding by a Third Party alleging
infringement or misappropriation of a Third Party Intellectual
Property Right as a result of the manufacture, use, sale, offer for
sale or import of a Product or the XOMA Materials, such Party shall
promptly notify the other Party in writing. Such written notice
shall include a copy of any summons or complaint (or the equivalent
thereof) received regarding the foregoing.

 

5.4 Cooperation. Each Party hereby
agrees:

 

(a) 

to cooperate in the
Patent Prosecution of any inventions within the Program Inventions
;

 

(b) 

to take all
reasonable additional actions and execute such agreements,
instruments and documents as may be reasonably required to perfect
the other Party’s ownership interest in the XOMA Materials
and the Program Inventions in accordance with the intent of this
Agreement;

 

(c) 

to provide comments
and suggestions, as reasonably requested by the other Party, with
respect to copies of drafts of material filings with or other
submissions to the U.S. Patent and Trademark Office or any foreign
counterpart (the “PTO”) relating to Patent
Prosecution, or the court or other tribunal relating to any
infringement claims against Third Parties under the TACTIC Patent
Rights or the defense of infringement or misappropriation claims by
Third Parties relating to Product;

 

(d) 

to cooperate, as
reasonably necessary, with the other Party in gaining patent term
extensions, supplemental protection certificates or their
equivalents wherever applicable to TACTIC Patent
Rights;

 

5.5 No Other Technology Rights.
Except as otherwise provided in this Agreement, under no
circumstances shall a Party, as a result of this Agreement, obtain
any ownership interest or other right in any invention, discovery,
Composition of Matter or other technology, or in any other
Intellectual Property Right, of the other Party (including without
limitation those owned, controlled or developed by the other Party
at any time pursuant to this Agreement).

 

ARTICLE
6

 

 

 

REPRESENTATIONS AND WARRANTIES

 

6.1 Each Party hereby
represents and warrants to the other Party as follows:

 

6.1.1 Existence.
Such Party is duly organized, validly existing and in good standing
under the laws of the jurisdiction in which it is
organized.

 

6.1.2 Authorization
and Enforcement of Obligations. Such Party (a) has the
requisite power and authority and the legal right to enter into
this Agreement and to perform its obligations hereunder, and (b)
has taken all necessary action on its part to authorize the
execution and delivery of this Agreement and the performance of its
obligations hereunder. This Agreement has been duly executed and
delivered on behalf of such Party, and constitutes a legal, valid,
binding obligation, enforceable against such Party in accordance
with its terms.

 

 

 

6.1.3 Consents.
All necessary consents, approvals and authorizations of all
governmental authorities and other Persons required to be obtained
by such Party in connection with this Agreement have been
obtained.

 

6.1.4 No
Conflict. The execution and delivery of this Agreement and
the performance of such Party’s obligations hereunder (a) do
not conflict with or violate any requirement of applicable laws or
regulations and (b) do not conflict with, or constitute a default
under, any contractual obligation of such Party.

 

6.1.5 Additional Representations of
TACTIC. TACTIC further represents and warrants that (a)
TACTIC was formed upon the
dissolution of ATTENUON, such that TACTIC can be considered a
lawful successor of ATTENUON; (b) TACTIC is the successor and rightful owner of
certain IP rights developed by ATTENUON, including, but not limited
to, ATN-658; (c) TACTIC will have in place by the start of a
Phase I clinical trial general liability and product liability
insurance with respect to the research, development and
commercialization of the TACTIC Target, the TACTIC Antibody and
Human EngineeredTM TACTIC Antibodies in such amounts as are
reasonable and customary in the biopharmaceutical industry and
covenants that it shall maintain appropriate general liability and
product liability insurance with respect thereto in such amounts
for so long as such research, development and commercialization
continues and thereafter for so long as is reasonable and customary
in the biopharmaceutical industry, and (d) TACTIC and its
Affiliates will have in place by the start of a Phase I clinical
trial appropriate policies and procedures intended to assure that
Confidential Information of XOMA, or other material non-public
information of XOMA, delivered or otherwise made available to
TACTIC will not be used by TACTIC or its officers, directors,
employees or agents in connection with any activity that would
constitute a criminal or civil violation of United States
securities laws and/or the regulations of the U.S. Securities and
Exchange Commission and, for so long as any provision of this
Agreement remains in effect, TACTIC covenants that it shall
maintain and enforce such policies and procedures and shall not
disclose any such Confidential Information of XOMA, or other
material non-public information of XOMA, to TACTIC's Affiliates who
do not then maintain and enforce such policies.

 

 

6.2 DISCLAIMER
OF WARRANTIES. EXCEPT AS OTHERWISE SET FORTH IN SECTION 6.1
OF THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE ANTIBODIES AND
OTHER INFORMATION DELIVERED OR TO BE DELIVERED PURSUANT TO THE
PRIOR AGREEMENT OR THE PROGRAM INVENTIONS, INCLUDING WITHOUT
LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE OR NON-INFRINGEMENT OF THE PATENT RIGHTS OR
OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY OTHER
PERSON.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

ARTICLE
7

 

 

 

TERM
AND TERMINATION

 

7.1 Term. Subject to
Sections 7.5 and 7.6 hereof, the term of this Agreement will
commence on the Effective Date and shall remain in full force and
effect until the expiration of all obligations of TACTIC under
Article 3, unless earlier terminated pursuant to 7.2 or 7.3 (the
period from the Effective Date through such expiration or earlier
termination being referred to herein as the “Term”). Upon such
expiration, TACTIC shall be deemed to have a fully paid-up license
to the rights set forth in Section 2.1.

 

7.2 Termination for Material
Breach. This Agreement may be terminated by the
non-breaching Party if the other Party is in breach of its material
obligations under this Agreement and after receiving notice
describing such breach in reasonable detail and requesting its cure
has not cured such breach within [***] days (in the case of a
payment breach with respect to any amount not being disputed in
good faith) or [***] days (in the case of a non-payment breach).
Notwithstanding the foregoing sentence of this Section 7.2: (a) if
such breach is cured or shown to be non-existent within the
aforesaid [***] days or [***] day period, the notice shall be
deemed automatically withdrawn and of no effect and the notifying
Party shall provide written notice to the breaching Party of the
withdrawal; and (b) without limiting the effects of the following
sentence of this Section 7.2, in the event of a good faith dispute
with respect to the existence of a material breach, the [***] day
or [***] day cure period shall be tolled until such time as the
dispute is resolved pursuant to Article 10. The Parties acknowledge
that any failure by XOMA to provide a Human EngineeredTM
TACTIC Antibody that meets the Success Criteria or that meets any
other technical objectives shall not in and of itself be deemed a
material breach of this Agreement.

 

7.3 Termination For Convenience.
This Agreement may be terminated without cause at any time upon
sixty (60) days prior written notice by TACTIC to XOMA, at
TACTIC’s discretion.

 

7.4 Contested Validity.
If TACTIC, a TACTIC successor, a TACTIC sublicensee of the rights
granted hereunder, or a person or entity Controlled by any of the
preceding entities, intends to challenge the validity or
enforceability of any of the XOMA Patent Rights, whether through a
declaratory judgment action, opposition, post-grant proceeding or
otherwise, then such entity shall: (a) [***] and (b)
[***].

 

 

7.5 Effect of
Termination.

 

7.5.1 Termination
of this Agreement shall not release either Party hereto from any
liability (including, without limitation, any payment obligation)
which, at the time of such termination, has already accrued to the
other Party or which is attributable to a period prior to such
termination nor preclude either Party from pursuing any rights and
remedies it may have hereunder or at law or in equity with respect
to any breach of this Agreement.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

7.5.2 Upon
any termination of this Agreement, TACTIC and XOMA shall (a)
promptly return to the other Party all Confidential Information
received from the other Party (except that each Party may retain
one copy for its files solely for the purpose of determining its
rights and obligations hereunder) or (b) destroy all such
Confidential Information with the other Party’s
consent.

 

Notwithstanding the survival of Article 2 as set
forth in Section 7.6 below, (a) the rights and licenses of TACTIC
under Section 2.1 shall terminate and be of no further force or
effect, and (b) TACTIC (on behalf of itself, its Affiliates, and
its successors and assigns) shall not (i) practice or exercise any
invention claimed in, or license, authorize or otherwise allow any
Third Party to practice or exercise such invention claimed in, any
XOMA Patent Rights or (ii) except as reasonably necessary to comply
with applicable law, regulation or court order as provided in
Section 4.2, use or disclose, or authorize or otherwise
allow the use or disclosure of, the XOMA Deliverables, upon (A)
termination of this Agreement by TACTIC pursuant to Section 7.3;
(B) termination of this Agreement by XOMA pursuant to Section 7.2
based on TACTIC 's failure to pay any amount due under Article 3
hereof and not being disputed in good faith; or (C) TACTIC 's
failure to pay a sum that had been disputed in good faith by the
Parties (together with all accrued interest due thereon under this
Agreement) within [***] days after a final determination by an
arbitrator pursuant to Section 9.3 that such amount is due under
this Agreement..

 

7.5.3 Nothing
herein shall in any way limit or restrict XOMA’s ability to
seek and obtain money damages, injunctive relief or any other
remedy, whether at law or in equity, that may be available from or
awarded by a court of competent jurisdiction based on, arising out
of or relating to any breach of this Agreement by
TACTIC.

 

7.5.4  Notwithstanding
anything to the contrary herein, XOMA shall not, at any time during
the Term or thereafter, use, or authorize or otherwise allow the
use of any Human EngineeredTM TACTIC Antibody.

 

7.6 Survival. Sections 3.5, 7.5 and
7.6, and Articles 1, 2 (including, subject to Section 7.5.2, all
rights and licenses therein), 4, 5, 6, 8, 9, 10 and 11 of this
Agreement shall survive any termination hereof.

 

ARTICLE
8

 

 

 

INDEMNITY

 

8.1 Indemnity.

 

 8.1.1 By
XOMA. XOMA shall indemnify and hold TACTIC harmless, and
hereby forever releases and discharges TACTIC, from and against all
losses, liabilities, damages and expenses (including reasonable
attorneys’ fees and costs) resulting from all claims,
demands, actions and other
proceedings by any Third Party to the extent arising from (a) the
breach of any representation, warranty or covenant
of XOMA under this or the Prior Agreement, (b) 
a claim that the
processes or technologies used by XOMA in the performance of its
activities under the Prior Agreement (other than any such claim
with respect to the CMV promoter), including, without limitation,
Human EngineeringTM activities, infringe the Intellectual
Property Rights of such Third Party (other than Intellectual
Property Rights to the TACTIC Target, any Antibody to the TACTIC
Target (including any Product), or (c) the gross negligence or willful
misconduct of XOMA, its Affiliates or sublicensees in the performance of its obligations, and its
permitted activities, under this or the Prior Agreement; in each case except to the
extent arising from the gross negligence or willful misconduct of
ATTENUON or TACTIC 

 

 

 

 8.1.2 By
TACTIC. TACTIC shall indemnify and hold XOMA harmless, and
hereby forever releases and discharges XOMA, from and against all
losses, liabilities, damages and expenses (including reasonable
attorneys’ fees and costs) resulting from all claims,
demands, actions and other proceedings by any Third Party to the
extent arising from (a) the breach of any representation, warranty
or covenant of ATTENUON or TACTIC under this or the Prior
Agreement, (b) excluding losses,
liabilities, damages and expenses covered by XOMA pursuant to
Section 8.1.1(b), the making, having made, using,
offering for sale, selling or importing of any Antibody to the
TACTIC Target (including without limitation any Human
EngineeredTM TACTIC
Antibody or Product) by ATTENUON, TACTIC, its Affiliates or
licensees or by XOMA pursuant to the terms of this Agreement, (c)
the use of the TACTIC Target or the
ATTENUON Deliverables by XOMA pursuant to the terms of the Prior
Agreement or (d) the gross negligence or willful misconduct
of ATTENUON, TACTIC, their Affiliates or licensees in the
performance of its obligations, and its permitted activities, under
this or the Prior Agreement; in each case except to the extent
arising from (i) a claim that the
processes used by XOMA in the performance of Human
EngineeringTM infringe the Intellectual Property Rights of
such Third Party (other than Intellectual Property Rights to the
TACTIC Target, any Antibody to the TACTIC Target, or
(ii) the gross negligence or willful misconduct of
XOMA. 

 

8.2 Procedure. A Party (the
“Indemnitee”) that intends
to claim indemnification under this Article 8 shall promptly notify
the other Party (the “Indemnitor”) of any
claim, demand, action or other proceeding for which the Indemnitee
intends to claim such indemnification. The Indemnitor shall have
the right to participate in, and to the extent the Indemnitor so
desires, to assume the defense thereof with counsel selected by the
Indemnitor; provided,
however, that the Indemnitee shall have the right to retain
its own counsel, with the fees and expenses to be paid by the
Indemnitor, if representation of the Indemnitee by the counsel
retained by the Indemnitor would be inappropriate due to actual or
potential differing interests between the Indemnitee and any other
Party represented by such counsel in such proceeding. The indemnity
obligations under this Article 8 shall not apply to amounts paid in
settlement of any claim, demand, action or other proceeding if such
settlement is effected without the prior express written consent of
the Indemnitor, which consent shall not be unreasonably withheld or
delayed. The failure to deliver notice to the Indemnitor within a
reasonable time after notice of any such claim or demand, or the
commencement of any such action or other proceeding, if prejudicial
to its ability to defend such claim, demand, action or other
proceeding, shall relieve such Indemnitor of any liability to the
Indemnitee under this Article 8 with respect thereto, but the
omission so to deliver notice to the Indemnitor shall not relieve
it of any liability that it may have to the Indemnitee otherwise
than under this Article 8. The Indemnitor may not settle or
otherwise consent to an adverse judgment in any such claim, demand,
action or other proceeding that diminishes the rights or interests
of the Indemnitee without the prior express written consent of the
Indemnitee, which consent shall not be unreasonably withheld or
delayed. The Indemnitee, its employees and agents shall reasonably
cooperate with the Indemnitor and its legal representatives in the
investigation and defense of any claim, demand, action or other
proceeding covered by this Article 8.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

ARTICLE
9

 

 

 

DISPUTE RESOLUTION

 

9.1 Attempts to Amicably Resolve
Disputes. If any dispute, controversy or claim is initiated
by either Party arising out of, resulting from or relating in any
way to this Agreement, the performance by either Party of its
obligations under this Agreement or the subject matter of this
Agreement (a “Dispute”), then the
Parties shall attempt to resolve such Dispute as follows. The Party
initiating the Dispute shall give written notice to the other
Party specifying in
reasonably specific detail the basis for such Dispute. Following
receipt of such notice, the Parties shall refer the Dispute to
their respective chief executive officers (or their designees) for
resolution. The Parties’ respective chief executive officers
(or their designees) shall meet (in person, by videoconference or
by telephone as mutually agreed upon by the Parties) to attempt to
reach a mutually acceptable resolution of the Dispute.

 

9.2 Mediation. Subject to Section
9.4, if a Dispute is not resolved in the manner set forth in
Section 9.1 within [***]
days after receipt of notice under Section 9.1, the Parties agree
to try in good faith to resolve such dispute in an expeditious
manner by mediation administered by the CPR Institute for Dispute
Resolution or its successor organization (“CPR”) in accordance with
its mediation procedure. The mediation proceeding shall be
conducted at the location of the Party not originally requesting
the resolution of the Dispute. The Parties agree that they shall
share equally the cost of the mediation filing and hearing fees and
the cost of the mediator. Each Party must bear its own
attorney’s fees and associated costs and expenses. For the
avoidance of doubt, nothing in connection with such mediation shall
be binding on either Party, except for the provisions regarding
sharing of costs set forth in this Section 9.2.

 

9.3 Arbitration.

 

9.3.1 Subject
to Section 9.4, any Dispute that is not resolved in the manner set
forth in Section 9.2 within [***] days after referral to
mediation under Section 9.2 shall be finally resolved by binding
arbitration, as set forth in this Section 9.3.

 

9.3.2 Whenever
a Party shall decide to institute arbitration proceedings, it shall
give written notice to that effect to the other Party. Any such
arbitration shall be conducted under the Commercial Arbitration
Rules of the American Arbitration Association by a panel of one (1)
arbitrator appointed in accordance with such rules to be appointed
within [***] days of such notice. Such arbitrator shall have no
less than [***] of experience directly in the field of
biotechnology licensing, and shall be available to serve under the
geographic and time constraints set forth herein and in Section
9.3.3. Any such arbitration shall be held in New York, New
York.

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

9.3.3 The
arbitrator shall be jointly instructed by the Parties in writing to
set a schedule that will enable them to complete all proceedings
and render their award within [***] days from the date of
appointment of the arbitrator in accordance with Section 9.3.2. For
good cause shown, the arbitrator may extend this schedule for up
to, but in no event more than, [***] additional days. The failure
of the arbitrator to render a final award within the foregoing time
frame shall not give rise to a jurisdictional defect, but this fact
shall not be disclosed to the arbitrators until after the
expiration of such [***] day period. The arbitrator shall have the
authority to grant specific performance in such equitable manner as
they determine. The prevailing Party in any such arbitration (as
determined by the arbitrator) shall be entitled to recover its
reasonable attorneys’ fees and expenses incurred in
connection with such arbitration. Judgment upon the award so
rendered may be entered in any court having jurisdiction as
provided in Section 9.5 or application may be made to such court
for judicial acceptance of any award and an order of enforcement,
as the case may be.

 

9.3.4 In
no event shall a demand for arbitration be made after the date when
institution of a legal or equitable proceeding based upon such
claim, dispute or other matter in question would be barred by the
applicable statute of limitations.

 

9.3.5 Notwithstanding
the foregoing, either Party shall have the right, without waiving
any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent
jurisdiction any interim or provisional relief that is necessary or
desirable to protect the rights or property of such Party, pending,
the selection of the arbitrators hereunder or pending the
arbitrators’ determination of any dispute, controversy or
claim hereunder.

 

9.4 Disputes Regarding Patents.
Notwithstanding any provision hereof to the contrary, any Dispute
relating to the determination of ownership, validity,
enforceability or infringement by the other Party of a
Party’s patents shall, if not resolved in the manner set
forth in Section 9.1 within [***] days after receipt of
notice under Section 9.1, be submitted exclusively to the federal
courts located in New York, New York , and the Parties hereby
consent to the jurisdiction and venue of such court.

 

9.5 Venue;
Jurisdiction.

 

9.5.1 Any
action or proceeding brought by either Party seeking to enforce any
provision of, or based on any right arising out of, this Agreement
must be brought against either Party in the courts of the State of
New York. Each Party (i) hereby irrevocably submits to the
jurisdiction of the state courts of the State of New York and to
the jurisdiction of any United States District Court in the State
of New York , for the purpose of any suit, action, or other
proceeding arising out of or based upon this Agreement or the
subject matter hereof brought by any Party or its successors or
assigns, (ii) hereby waives, and agrees not to assert, by way of
motion, as a defense, or otherwise, in any such suit, action, or
proceeding, any claim that it is not subject personally to the
jurisdiction of the above-named courts, that its property is exempt
or immune from attachment or execution, that the suit, action or
proceeding is brought in an inconvenient forum, that the venue of
the suit, action, or proceeding is improper or that this Agreement
or the subject matter hereof may not be enforced in or by such
court, and (iii) hereby waives and agrees not to seek any review by
any court of any other jurisdiction that may be called upon to
grant an enforcement of the judgment of any such Illinois state or
federal court.

 

 

 

9.5.2 Process
in any action or proceeding seeking to enforce any provision of, or
based on any right arising out of, this Agreement may be served on
any Party anywhere in the world. Each Party consents to service of
process by registered mail at the address to which notices are to
be given pursuant to Section 11.4. Nothing herein shall affect the
right of a Party to serve process in any other manner permitted by
applicable law. Each Party further agrees that final judgment
against it in any such action or proceeding arising out of or
relating to this Agreement shall be conclusive and may be enforced
in any other jurisdiction within or outside the United States of
America by suit on the judgment, a certified or exemplified copy of
which shall be conclusive evidence of the fact and of the amount of
its liability.

 

9.5.3 Each
Party agrees that it shall not, and that it shall instruct those in
its control not to, take any action to frustrate or prevent the
enforcement of any writ, decree, final judgment, award (arbitral or
otherwise) or order entered against it with respect to this
Agreement, and shall agree to be bound thereby as if issued or
executed by a competent judicial tribunal having personal
jurisdiction situated in its country of residence or
domicile.

 

ARTICLE
10

 

 

 

SUCCESSORS AND ASSIGNS

 

10.1 Limited
Right to Assign. Neither TACTIC nor XOMA may transfer or
assign this Agreement or any of its rights hereunder without the
written consent of the other;
provided,
however, that (a) XOMA may,
without such consent, assign this Agreement and its rights and
obligations hereunder to a Third Party only in connection with the
transfer or sale of all or substantially all of its business
relating to Human EngineeringTM, or in the event of a merger,
consolidation or other transaction resulting in a change in control
of XOMA, and (b) TACTIC may, without such consent, assign this
Agreement and its rights and obligations hereunder to a Third Party
only in connection with the transfer or sale of a Human
EngineeredTM version of a TACTIC Antibody or all or
substantially all of its assets relating to its anti-uPAR
monoclonal antibodies or in the event of a merger, consolidation or
other transaction resulting in a change in control of TACTIC. Any
attempted transfer or assignment in violation of this Section 10.1
shall be void. Nothing herein shall prohibit any transfer or
assignment by either TACTIC or XOMA to or among any of their
respective Affiliates.

 

10.2 Permitted
Successors and Assigns. This Agreement shall be binding upon
and inure to the benefit of the Parties and their successors and
assigns as permitted in Section 10.1.

 

ARTICLE
11

 

 

 

MISCELLANEOUS

 

11.1 Governing
Law. This Agreement and any dispute arising from the
performance or breach hereof shall be governed by and construed and
enforced in accordance with the laws of the State of New York,
without reference to conflicts of laws principles.

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

11.2 Bankruptcy.
All rights and licenses granted under or pursuant to this Agreement
by one Party to the other are, for all purposes of Section 365(n)
of Title XI of the United States Code (“Title XI”), licenses of
rights to “intellectual property” as defined in Title
XI. During the Term each Party shall create and maintain current
copies to the extent practicable of all such intellectual property.
If a bankruptcy proceeding is commenced by or against one Party
under Title XI, the other Party shall be entitled to a copy of any
and all such intellectual property and all embodiments of such
intellectual property, and the same, if not in the possession of
such other Party, shall be promptly delivered to it (a) upon such
Party’s written request following the commencement of such
bankruptcy proceeding, unless the Party subject to such bankruptcy
proceeding, or its trustee or receiver, elects within [***] days to
continue to perform all of its obligations under this Agreement, or
(b) if not delivered as provided under clause (a) above, upon such
other Party’s request following the rejection of this
Agreement by or on behalf of the Party subject to such bankruptcy
proceeding. If a Party has taken possession of all applicable
embodiments of the intellectual property of the other Party
pursuant to this Section 11.2 and the trustee in bankruptcy of the
other Party does not reject this Agreement, the Party in possession
of such intellectual property shall return such embodiments upon
request. If a Party seeks or involuntarily is placed under Title XI
and the trustee rejects this Agreement as contemplated under 11
U.S.C. 365(n)(1), the other Party hereby elects, pursuant to
Section 365(n) of Title XI, to retain all rights granted to it
under this Agreement to the extent permitted by law.

 

11.3 Waiver.
No waiver of any rights shall be effective unless consented to in
writing by the Party to be charged and the waiver of any breach or
default shall not constitute a waiver of any other right hereunder
or any subsequent breach or default.

 

11.4 Notices.
All invoices, notices, requests and other communications hereunder
shall be in writing and shall be delivered or sent in each case to
the respective address specified below, or such other address as
may be specified in writing to the other Party hereto, and shall be
effective on receipt.

 

If to
TACTIC: 

Tactic Pharma,
LLC

 

   
           
           
           
           
           
         
[***]

 

   
           
           
           
           
           
        Attention: Andrew Mazar,
CSO.

 

With a copy
to: 

Baker &
Hostetler, LLP 2929 Arch Street

 

Cira
Centre – 12th Floor

 

Philadelphia, PA
19004

 

Attention: Tactic
Pharma Legal Counsel, Dr. Jeffrey H. Rosedale

 

If to
XOMA: 

XOMA (US)
LLC

 

   
           
           
           
           
           
         2910 Seventh
Street

 

   
           
           
           
           
           
        Berkeley, California
94710

 

   
           
           
           
           
           
        Attention: Legal
Department

 

 

 

with a copy
to: 

XOMA (US)
LLC

 

   
           
           
           
           
           
          2910 Seventh
Street

 

   
           
           
           
           
           
          Berkeley, California
94710

 

   
           
           
           
           
           
          Attention: Legal
Department

 

11.5 Independent
Contractors. The Parties are independent contractors under
this Agreement. Nothing contained in this Agreement is intended nor
is to be construed so as to constitute TACTIC or XOMA as partners
or joint venturers with respect to this Agreement. Except as
expressly provided for by this Agreement, no Party shall have any
express or implied right or authority to assume or create any
obligations on behalf of or in the name of any other Party or to
bind any other Party to any other contract, agreement or
undertaking with any Third Party.

 

11.6 Force
Majeure. A Party shall neither be held liable or responsible
to the other Party, nor be deemed to have defaulted under or
breached this Agreement, for failure or delay in fulfilling or
performing any obligation under this Agreement (other than an
obligation for the payment of money) to the extent, and for so long
as, such failure or delay is caused by or results from causes
beyond the reasonable control of such Party, including but not
limited to fire, floods, embargoes, war, acts of war (whether war
be declared or not), insurrections, riots, civil commotions,
strikes, lockouts or other labor disturbances, acts of God or acts,
omissions or delays in acting by any governmental authority or
other Party.

 

11.7 Other
Activities. Except as otherwise expressly provided in this
Agreement, nothing in this Agreement shall preclude either Party
from conducting other programs (either for its own benefit or with
or for the benefit of any other Person) to conduct research, or to
develop or commercialize products or services, for use in any
field.

 

11.8 Headings.
The captions to the several sections hereof are not a part of this
Agreement, but are included merely for convenience of reference
only and shall not affect its meaning or
interpretation.

 

11.9 Entire
Agreement; Amendment.

 

11.9.1 This
Agreement constitutes the entire and exclusive agreement between
the Parties with respect to the subject matter hereof and
supersedes and cancels all previous discussions, agreements,
representations, commitments and writing in respect
thereof.

 

11.9.2 No
amendment or addition to this Agreement shall be effective unless
reduced to writing and executed by the authorized representatives
of the Parties.

 

11.10 Illegality;
Unenforceability. In the event that any provision of this
Agreement shall be determined to be illegal or unenforceable, that
provision will be limited or eliminated to the minimum extent
necessary so that this Agreement shall otherwise remain in full
force and effect and enforceable.

 

11.11 Counterparts.
This Agreement may be executed in counterparts, each of which shall
be deemed to be an original and together shall be deemed to be one
and the same agreement.

 

[SIGNATURE PAGE
FOLLOWS ]

 

 

 

 

 

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the
date first set forth above.

 

 

 

	

         TACTIC PHARMA,
LLC

 

 

 

By: /s/ Andrew
Mazar

Andrew
Mazar

           
Chief Scientific Officer

 

	

XOMA
(US) LLC

 

 

 

By: /s/ James
Neal

James R. Neal

VP, Business Development & Program
Leadership

 

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

Schedule
1.16

 

Human EngineeringTM Patent Rights

 

Title: 

[***]

Inventors:                                Studnicka,
Little, Fishwild, Kohn

 

 

Based
on [***].

 

	

COUNTRY

	

SERIAL NO.

	

PATENT NO.

	

EXPIRES

	

[***]

	

[***]

	

[***]

	
[***]

 

[***]

 

 

 

 

 

 

-1-Blueprint

 

 

[***] = Confidential Information has been
omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

CONTRIBUTION AGREEMENT (351)

 

            

This Contribution
Agreement (this “Agreement”) is
entered into as of August 25, 2017 (the “Effective
Date”), among TacticGem LLC, a Delaware limited
liability company (the “Company”),
Monopar Therapeutics Inc., a Delaware corporation
(“Monopar”), Gem
Pharmaceuticals, LLC, an Alabama limited liability company
(“Gem”) and
Tactic Pharma, LLC, an Illinois limited liability company
(“Tactic”, and
collectively with Gem, the owners of 100% of the issued and
outstanding limited liability company interests of the Company).
The Company, Monopar, Tactic, and Gem are sometimes hereinafter
referred to collectively as the “Parties”, and
each individually as a “Party”.

 

BACKGROUND INFORMATION

 

A.           The
parties have entered into that certain Contribution Agreement by
and among the Company, Tactic, and Gem, dated as of August 24, 2017
(the “721
Contribution Agreement”) whereby Gem contributed to
the Company all of Gem’s right, title and interest in and to
the property and assets described on Exhibit A attached hereto
(collectively, the “Gem Contributed
Assets”) and Tactic contributed to the Company the
Tactic Contributed Assets (as defined in the 721 Contribution
Agreement).

 

B.           Pursuant
to this Agreement and subsequent to the contributions contemplated
by the 721 Contribution Agreement, the Company will contribute (the
“Company
Contribution”) to Monopar all of the Company’s
right, title and interest in and to the Gem Contributed Assets in
exchange for 3,055,394.12 shares of Monopar’s common stock.
Subsequent to the transactions contemplated by the 721 Contribution
Agreement and this Agreement, the Company will own 7,166,667 shares
of Monopar common stock, which will constitute 79.70% of the total
number of shares outstanding of Monopar. By a separate agreement
(the “Investor Contribution
Agreement”), entered into on or before this Agreement,
between Monopar and a third party investor (the “Investor”),
the Investor will contribute $2,000,004 to Monopar in exchange for
333,334 shares of common stock (the “Investor
Contribution”, and together with the Company
Contribution, the “351
Transaction”). The Company and the Investor,
collectively, will own at least 80% of the total combined voting
power of all classes of stock entitled to vote and at least 80% of
the total number of shares of all classes of stock of Monopar
subsequent to the 351 Transaction.

 

C.           It
is the intent of the Parties hereto that the 351 Transaction
constitutes a tax-free transfer pursuant to Section 351 of the
Internal Revenue Code of 1986, as amended.

 

 

 

STATEMENT OF AGREEMENT

 

NOW,
THEREFORE, in consideration of the mutual covenants herein
contained and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the Parties
agree as follows:

 

ARTICLE I

COMPANY CONTRIBUTION

 

§1.1           

Contribution. As of the Effective Date, (a) the Company hereby
contributes the Gem Contributed Assets to Monopar, and (b) Monopar
hereby accepts the Gem Contributed Assets, and assumes and
agrees to perform all obligations, restrictions and conditions
which are applicable to the Gem Contributed Assets to the extent
such obligations arise or accrue from and after the Effective Date
(except as otherwise provided in this Agreement). Monopar does not
assume or otherwise accept responsibility for any Liabilities (as
defined in the 721 Agreement) or obligations of Gem, Tactic, or the
Company, provided that Monopar will assume the obligations of Gem
accruing or arising after the Effective Date under the agreements
listed on the attached Exhibit B (the
“Assigned
Contracts”), with Gem being responsible for all such
liabilities and obligations accruing or arising prior to the
Effective Date.

 

§1.2           Shares
Issued. In exchange for the Gem
Contributed Assets, Monopar shall issue 3,055,394.12 shares
of its common stock (the “Issued Stock”)
to the Company. The Company shall hold
such shares as a separate block of stock that may be specifically
indentified as separate from the other 4,111,272.88 shares of
Monopar common stock held by the Company.

 

ARTICLE II

REPRESENTATIONS AND WARRANTIES

 

§2.1           

Representations and Warranties
of the Company, Tactic, and Gem. The representations and warranties of the Company,
Tactic, and Gem set forth in Article 5 of the 721 Agreement are
hereby made by them to Monopar and incorporated by reference in
this Agreement as if fully rewritten herein.

 

§ 2.2                      

Representations and Warranties
of Monopar. Monopar hereby represents and warrants to each
of the other Parties hereto that the statements contained in
this §2.2 are, except as would not be reasonably expected to
have a material adverse effect, true and correct as of the
Effective Date.

 

(a)           

Organization;
Authority; Enforceability.
Monopar is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware, and
has full corporate power and authority to execute and deliver this
Agreement and perform its obligations hereunder. This Agreement
constitutes the legal, valid, and binding obligation of Monopar,
enforceable against Monopar in accordance with its terms, subject
to the effects of bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium, and other similar laws relating to
and/or affecting creditors’ rights generally and to general
equitable principles. The Issued Stock, when issued pursuant to the
terms and conditions of this Agreement, will be duly authorized,
validly issued, fully paid, and non-assessable, and issued in
compliance with all applicable federal and state securities
laws.

 

 

 

(b)           Non-Contravention.
Neither the execution and delivery of this Agreement, nor the
consummation of the transactions contemplated hereby, will (i)
violate any constitution, statute, regulation, rule, injunction,
judgment, order, decree, ruling, charge, or other restriction of
any government, governmental agency, or court to which
Monopar is subject or
any provision of Monopar’s Organizational Documents or any
other governing document of Monopar or (ii) conflict with, result
in a breach of, constitute a default under, result in the
acceleration of, create in any party the right to accelerate,
terminate, modify, or cancel, or require any notice under any
agreement, contract, lease, license, instrument, or other
arrangement to which any assets of Monopar are subject (or result
in the imposition of any Encumbrance upon any assets of
Monopar).

 

(c)           Private
Placement Memorandum of Monopar. The Private Placement Memorandum of Monopar dated
August 22, 2017, which includes the private placement memorandum
dated March 25, 2017 (the “PPM”)
contains information about Monopar. The PPM was prepared for an
offering limited to accredited investors and does not contain all
of the information that would be included in a registration
statement filed with the SEC. Monopar is not aware of any
inaccurate statements of fact in the PPM.

 

(d)           Capitalization.
(i) The authorized capital of Monopar as of July 31, 2017 consisted
of 40,000,000 shares of common stock, $0.001 par value per share,
and 8,675,919.61 shares of common stock outstanding
(non-dilutive); (ii) on a fully
diluted basis, accounting for all issued options, there were
9,231,439.61 shares of common stock outstanding as of July 31,
2017; (iii) following the surrender of 2,888,727.12 shares of
Tactic’s Monopar common stock back to Monopar, Monopar would
have shares outstanding of 5,787,192.5 shares of common stock
(non-dilutive), and 6,342,712.5 shares of common stock on a
fully-diluted basis; and (iv) 700,000 shares of Common Stock have
been reserved for issuance under Monopar’s 2016 Stock
Incentive Plan, of which 555,520 shares are subject to issued and
outstanding options. All outstanding shares of Monopar common stock
have been duly authorized and validly issued, are fully paid
and non-assessable, and to Monopar’s knowledge, issued in
compliance with all applicable federal and state securities
laws.

 

 

(e)           

Disclosure. No representation
or warranty or other statement made by Monopar in this Agreement,
or otherwise in connection with the transactions contemplated
hereby contains any material untrue statement or omits to state a
material fact necessary to make any of them, in light of the
circumstances in which it was made, not misleading in any adverse
respect.

 

 

 

(f)           No
Other Representations and Warranties. Except for the
representations and warranties set forth in this Agreement, each of
the Company, Tactic, and Gem acknowledges and agrees that no
representation or warranty of any kind whatsoever, express or
implied, at law or in equity, is made or shall be deemed to have
been made by or on behalf of Monopar to the Company, Tactic, or
Gem, and Monopar hereby disclaims any such representation or
warranty, whether by or on behalf of Monopar. 

 

 

 

ARTICLE III

POST-CLOSING MATTERS

 

§3.1           Tax
Matters. Each Party
shall cooperate fully, as and to the extent reasonably requested by
any other Party, in connection with the preparation and filing of
any Tax Return (as defined in the 721 Agreement) and any audit with
respect to Tax (as defined in the 721 Agreement), with respect to
the Gem Contributed Assets. Such cooperation shall include the
retention and, upon request, the provision of records and
information which are reasonably relevant to any such Tax Return or
audit or any tax planning and shall also include making employees
available on a mutually convenient basis to provide additional
information and explanation of any material provided hereunder.
Each Party further agrees, upon request, to use its commercially
reasonable efforts to obtain any certificate or other document from
any taxing authority or any other individual, corporation,
partnership, limited liability company, association, trust or any
other entity or organization as may be necessary to mitigate,
reduce or eliminate any Tax that could be imposed (including any
sales, use, documentary, stamp, gross receipts, registration,
transfer, conveyance, excise, recording, license, stock transfer
stamps and other similar taxes and fees arising out of or in
connection with or attributable to the transactions effected
pursuant to this Agreement (collectively, “Transfer
Taxes”; but for purposes of clarification, Transfer
Taxes do not include any income taxes incurred by or allocable to
any party in connection with or
attributable to the transfer of the Gem Contributed Assets, and the
transactions affected pursuant to this Agreement). The
Company shall bear and be responsible for the timely payment of,
and to such extent shall indemnify and hold harmless Monopar
against any Transfer Taxes, and Gem and Tactic shall each in turn
bear and be responsible for the timely payment of, and to such
extent shall indemnify and hold harmless the Company against, fifty
percent (50%) of such Transfer Taxes so paid.

 

§3.2           Consulting
Relationship with Gem Personnel. Each of Gerald M. Walsh and Richard D. Olson shall
become consultants of Monopar at the Effective Date and Monopar
will execute a consulting agreement with such individuals in
substantially the form of the attached Exhibit
C.

 

§ 3.3                      Indemnification.

 

(a) Notwithstanding any investigation
conducted at any time with regard thereto, by or on behalf of the
Company, Tactic, Gem or Monopar, all representations, warranties,
covenants and agreements of the Parties in this Agreement
(including those incorporated by reference) and in any other
documents executed or delivered by any of them pursuant to this
Agreement or in connection with the transactions contemplated by
this Agreement (collectively, the “Additional
Documents”) shall survive the execution, delivery, and
performance of this Agreement and the Additional
Documents.

 

 

 

(b) (i)
Each Party shall defend, indemnify and hold harmless the other
Parties, and their directors, officers, employees and
representatives from and against any and all Damages asserted
against, resulting to, imposed upon, or incurred or suffered by
such Party, directly or indirectly, as a result of or arising from
any Indemnifiable Claims as set forth in Sections 9.2, 9.3, 9.4, 9.5, 9.7, 9.8 and 9.9 of
the 721 Contribution Agreement (the “Indemnification
Provisions”), which are
hereby incorporated by reference; and (ii) Monopar shall
defend, indemnify and hold harmless each of the Parties from and
against any and all Damages asserted against, resulting to, imposed
upon, or incurred or suffered by Gem, directly or indirectly, as a
result of or arising from any material breaches of the
representations and warranties of Monopar in §2.2 pursuant to
the Indemnification Provisions.
Indemnification by any Party to this Agreement shall be governed by
the Indemnification Provisions. References to the
“Agreement” in such Sections shall be interpreted to
refer to this Agreement in the context of Indemnifiable Claims
under this Agreement.

 

§3.4. Tax Treatment. Each of the Parties
acknowledges and agrees that the contribution of the Gem
Contributed Assets to Monopar is intended to qualify for treatment
as an exchange described in Section 351(a) of the Internal Revenue
Code of 1986, as amended (the "Code"). All Parties agree to
prepare or cause to be prepared their Tax Returns in accordance
with the immediately preceding sentence, including complying with
the record keeping requirements of Treasury Regulation Section
1.351-3.

 

ARTICLE
IV

REGISTRATION RIGHTS

 

§ 4.1 Registration
Rights.

 

(a)
Monopar shall, upon direction by the Company at any time after
Monopar has been subject to the reporting requirements of the
Securities and Exchange Act of 1934 for at least 12 months (the
“Initial
Holding Period”), file with the U.S. Securities and
Exchange Commission (“SEC”) a Form S-3 or other
appropriate form of registration statement, covering the resale of
any Monopar common stock by the Company, Gem, or Tactic and shall
use its best efforts to have such registration statement declared
effective as soon as practical thereafter. During the period that
the registration statement is effective, Monopar shall make all
public filings required in the normal course of its business and
necessary to maintain the effectiveness of the registration
statement during the period of resale of any Monopar common stock
by the Company, Gem, or Tactic; provided that the Company, Gem, and
Tactic agree that Monopar may, from time to time, inform the
Company, Gem, and Tactic that it may not sell Monopar common stock
until further notice if circumstances exist which have not been
disclosed publicly and the omission of which, in the reasonable
opinion of Monopar, would result in a material omission of fact in
the registration statement. The Company, Gem, and Tactic agree that
upon receipt of such notice and until otherwise informed by
Monopar, the Company, Gem, and Tactic shall not sell, or permit to
be

 

 

 

sold,
the Monopar common stock. The Company, Gem, and Tactic acknowledge
that Monopar cannot guarantee receipt of approval from the SEC, and
in the event that approval is not granted, the Company, Gem, and/or
Tactic, as applicable, must hold the Monopar common stock until
such time as the Company, Gem, and/or Tactic may be permitted to
sell the Monopar common stock pursuant to applicable securities
laws or exemptions therefrom. Monopar shall pay the costs to
prepare and file the registration statement, including the
registration fee due to the SEC and all legal and accounting
expenses and the cost of compliance with the securities or blue sky
laws in the State of Delaware or any other state. The Company, Gem,
or Tactic, as applicable (the party which is the seller of such
Monopar common stock) shall pay all other costs of sale of the
Monopar common stock, including any underwriting fees, commissions
on sale or stock transfer taxes resulting from the sale of the
Monopar common stock. In the event that a registration statement
for the resale of the Monopar common stock is not approved by the
SEC, Monopar shall, upon written request of the Company, prepare
and file a registration statement on Form S-1 registering for sale
any of the common stock and use its best efforts to have such
registration statement declared effective as soon as practical
thereafter. Monopar shall pay the costs to prepare and file such
registration statement, including the registration fee due to the
SEC and all legal and accounting expenses and the cost of
compliance with the securities or blue sky laws in the State of
Delaware or any other State. Additionally, the Company, Gem, and
Tactic shall receive the piggyback registration rights set forth in
(b) below.

 

 (b)           At
any time following the Effective Date (but without obligation to do
so) if Monopar proposes to register any of its common stock under
the Securities Act of 1933, as amended (the “Securities
Act”) in connection with the public offering of such
securities solely for cash (other than a registration effected
solely to implement an employee benefit plan or a transaction to
which Rule 145 of the Securities Act is applicable or a
registration using any form that does not permit secondary sales of
securities), Monopar will give written notice to the Company, Gem,
and Tactic of its intention to do so and, upon written request of
the Company, Gem, or Tactic, delivered to Monopar within 15 days
after receipt of notice, Monopar will use its best efforts at its
own expense (but excluding any underwriting commissions and stock
transfer taxes accruing to any common stock registered by the
Company, Gem, or Tactic) to cause to be registered under the
Securities Act the shares of common stock specified by the Company,
Gem, or Tactic, subject to (1) the right of other holders of
restricted stock to include their stock in any such registration
prior to the inclusion of the common stock, including but not
limited to rights of parties acquiring shares of common stock under
any agreement that Monopar will register the resale thereof, (2)
the Company’s acceptance of the terms of any underwriting
agreement entered into or proposed to be entered into between
Monopar and any underwriter of such offering, and (3) if the sole
or managing underwriter of such offering determines that the
aggregate number of shares of common stock which have been
requested by the Company, Gem, or Tactic to be included in the
registration should be limited to a lesser number or not included
due to market conditions, then Monopar may only sell the lesser
portion, if any. If a limitation is imposed on the number of common
stock includable by Monopar in any such offering, Monopar shall
give the Company, Gem, and Tactic, as applicable, prompt written
notice thereof.

 

§4.2              Form
10. Monopar shall
exert its commercially reasonable best efforts to cause to be filed
with the Securities and Exchange Commission (the
“SEC”),
under the Securities Exchange Act of 1934 (the “1934 Act”), a
registration statement on Form 10 (or another appropriate form), to
register Monopar’s shares of common stock, $0.001 par value
per share, within ninety (90) days after the Effective
Date. 

 

 

ARTICLE V

MISCELLANEOUS PROVISIONS

 

§5.1           Severability.
Any term or provision of this Agreement that is invalid or
unenforceable in any situation in any jurisdiction (as determined
by a court) shall not affect the validity or enforceability of the
remaining terms and provisions hereof or the validity or
enforceability of the offending term or provision in any other
situation or in any other jurisdiction.

 

 

 

§5.2           Notices.
All notices, requests, demands, claims, and other communications
hereunder shall be made as set forth in Section 11.1 of the 721
Contribution Agreement.

 

§5.3           Construction.
The parties have participated jointly in the negotiation and
drafting of this Agreement. In the event an ambiguity or question
of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties and no presumption
or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any of the provisions of this
Agreement. Any reference to any federal, state, local, or foreign
statute or law shall be deemed also to refer to all rules and
regulations promulgated thereunder, unless the context requires
otherwise.

 

§5.4           Entire
Agreement; Amendment; Waivers, etc. This Agreement
(including its schedules and exhibits), along with the 721
Agreement and the Investor Contribution Agreement constitutes the
entire agreement among the Parties and supersedes all prior
agreements and understandings, agreements or representations by or
among the Parties, written and oral, with respect to their subject
matter. No amendment, supplement, waiver or termination of this
Agreement is binding unless executed in writing by the Party to be
bound thereby. No waiver of any of the provisions of this Agreement
constitutes a waiver of any other provision of this Agreement,
whether or not similar, unless otherwise expressly
provided.

 

§5.5           Successors
and Assigns. Except as otherwise expressly permitted in this
Agreement, the Parties agree not to assign this Agreement or any of
the rights, interests, or obligations hereunder to any other person
or entity (whether in whole or in part, whether directly or
indirectly, and whether voluntarily or, to the fullest extent
permitted by applicable law, involuntarily), except with the prior
written consent of the other Party, which consent such Party may
grant or withhold in its sole discretion, and which consent, if
granted, does not imply any other consent in the future. Any
purported assignment in violation of this Section will be void and
of no legal effect. This Agreement will inure to the benefit of and
be binding upon each Party to this Agreement and each Party’s
successors, heirs, permitted assigns, and legal
representatives.

 

§5.6           Captions.
The headings of the Sections and Articles of this Agreement are
inserted for convenience only and shall not constitute a part
hereof or affect in any way the meaning or interpretation of this
Agreement.

 

§5.7           Counterparts.
This Agreement may be executed in any number of separate
counterparts (including facsimile and electronic transmission),
each of which upon execution and delivery will constitute an
original and all of which taken together will constitute one
agreement.

 

§5.8           Governing
Law; Consent to Jurisdiction and Venue.

 

(a)           THIS
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH,
THE LAWS OF THE STATE OF DELAWARE, WITHOUT GIVING EFFECT TO ANY
CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE
STATE OF DELAWARE OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE
LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF DELAWARE TO BE
APPLIED.

 

 

 

(b)           Each of
the Parties hereto irrevocably submits itself to the exclusive
jurisdiction of the United States District Court of the Northern
District of Illinois (unless such court lacks jurisdiction under
Applicable Law, in which case each Party submits itself exclusively
to the jurisdiction of the state courts of Illinois sitting in Cook
County) for the purpose of any Action arising out of or relating to
this Agreement and/or the transactions contemplated
hereby.

 

(c)           Each
of the Parties hereto irrevocably agrees that all claims with
respect to any such Action arising out of or relating to this
Agreement and/or the transactions contemplated hereby shall be
heard and determined exclusively in United States District Court of
the Northern District of Illinois (unless such court lacks
jurisdiction under Applicable Law, in which case each Party submits
itself exclusively to the jurisdiction of the state courts of
Illinois sitting in Cook County).

 

 

§ 5.9                      WAIVER
OF JURY TRIAL. AS A SPECIFICALLY BARGAINED INDUCEMENT FOR
EACH OF THE PARTIES TO ENTER INTO THIS AGREEMENT (EACH PARTY HAVING
HAD OPPORTUNITY TO CONSULT COUNSEL), EACH PARTY EXPRESSLY WAIVES
THE RIGHT TO TRIAL BY JURY IN ANY LAWSUIT, ACTION OR PROCEEDING
RELATING TO OR ARISING IN ANY WAY FROM THIS AGREEMENT OR ANY
TRANSACTIONS RELATED HERETO OR CONTEMPLATED HEREBY.

 

 

§ 5.10                      Defined
Terms. Any terms not defined in this Agreement shall have
the meanings assigned to them in the 721 Agreement.

 

 

The
Parties have duly executed this Agreement as of the date first
above written.

 

 

	

MONOPAR THERAPEUTICS, INC.

	

TACTICGEM LLC

 

By: CDR
Pharma LLC

Its:
Manager

 

	

By:/s/ Chandler
Robinson

Chandler Robinson, CEO

	

By: /s/ Chandler Robinson

Its:
Member of the Manager

	

 

 

TACTIC PHARMA, LLC

 

	

 

 

GEM PHARMACEUTICALS, LLC

	

By: /s/ Chandler
Robinson

Its: Manager

	

By: /s/ Arthur
Klausner

Arthur Klausner, CEO

 

 

 

 

 

 

 

 

 

EXHIBIT
A

 

 

Gem
Contributed Assets

 

See
Attached.

 

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

“Gem
Contributed Assets” means, collectively, the following (each
as defined herein):

 

1.           
$5,000,000 in cash.

2.            

All right, title
and interest, tangible and intangible, in and to the following
(individually and collectively, the
“Compounds”):

a.            

GPX-100

b.            

GPX-150

c.            

GPX-160

d.            

GPX-170

e.            

GPX-180

3.            

The Related
Assets

4.            

All of the Gem
Contributed Intellectual Property

5.            

All of the Gem
Contracts including:

a.            

License
Agreements

b.            

Research and
Collaboration Agreements

c.            

Manufacturing,
Clinical Research and Compound Storage Agreements

6.            

All inventory of
product, including raw materials, work in process and finished
product

7.            

All works-made-for
hire agreements relating to the Compounds.

8.            

After Closing, Gem
will use reasonable good faith efforts to cause Monopar and the
Company to be added as additional insureds to its product liability
and comprehensive general liability insurance policies (the
“Gem Insurance Policies”). Such rights as additional
insureds shall be transferred to each of Monopar and the Company
and shall be considered Gem Contributed Assets.

 

B.            

“GPX-150”
means:

 

1.
[***]

2.
[***]

3. Any
[***]

4.
[***]

5. Any
formulation of [***]

6. Any
uses of [***]

 

C.            

“GPX-160”
means:

 

1.            

[***]

2.            

[***]

3.            

[***]

4.            

Any formulation of
[***]

5.            

Any uses of
[***]

 

D.            

“GPX-100”
means:

 

1.
[***]

2.
[***]

3.
[***]

4.
[***]

5. Any
formulation of [***]

6. Any
uses of [***]

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

E.            

“GPX-170”
means:

 

1.
[***]

2.
[***]

3. Any
[***]

4.
[***]

5. Any
formulation of [***]

6. Any
uses and formulations of [***] and

 

F.            

“GPX-180”
means:

 

1.
[***]

2.
[***] and [***].

3. Any
[***]

4.
[***]

5. Any
formulation of [***]

6. Any
uses and formulations of [***]

 

G.            

“Related
Assets” means:

 

1.            

All assets related
to Gem’s use and development of the Compounds (including
without limitation [***] for any purpose, all assets used by Gem,
and necessary or useful to Gem as of Closing, in conducting
research, development, testing, marketing, selling, manufacturing
and/or distributing the Compounds and any other analogs derived
from them and their use (including without limitation [***] or any
other analogs derived from GPX-100, GPX-150, GPX-160, GPX-170, or
GPX-180)) as such activity is presently conducted and as such
activity is presently planned to be conducted, including, but not
limited to, all inventory of Compounds, all other inventory,
agreements, contracts, licenses, Intellectual Property related to
or useful for the Business, intellectual property assignments, ,
orphan drug or other regulatory designations, pending orphan drug
or other regulatory applications, trademarks, service marks and all
goodwill associated therewith, pre-clinical and clinical data,
manufacturing equipment; anthracycline molecules that,
[***].

2.            

The
[***].

3.            

Manufacturing
agreements.

4.            

Written reports,
regulatory documents, case reports, and manufacturing
methods.

5.            

All FDA and other
regulatory authorities filings and scientific studies relating to
the Compounds and the Related Assets including the
following:

a.            

Orphan drug
designation [***]

b.            

[***] GPX-150
[***]. All relevant filings and approvals in the US for GPX-150
have been made to this IND and are part of the IND record. [Date
February 7, 2007]

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

 

H.            

“Gem
Contributed Intellectual Property” has the meaning set forth
in Section 10 of the Agreement. “Intellectual Property”
means:

 

All
domestic and foreign (1) patents and patent applications, and all
patents issuing thereon, including without limitation utility,
model and design patents and certificates of invention, together
with all reissue patents, patents of addition, divisionals,
provisional applications, renewals, continuations,
continuations-in-part, substitutions, additions, extensions,
confirmations, re-examinations, and all foreign counterparts of the
forgoing which are in the process of being prepared, and all
inventions and improvements disclosed therein including the right
to claim priority benefit of or to any of the foregoing
(collectively, “Patents”); (2) trademarks, service
marks, trade dress, trade names, brand names, designs, logos,
commercial symbols and corporate names, and all registrations,
applications and goodwill associated therewith (collectively,
“Trademarks”); (3) copyrights and all works of
authorship, whether or not registered or copyrightable, and all
applications, registrations, and renewals in connection therewith
(collectively, “Copyrights”); (4) confidential and
proprietary information, including without limitation, trade
secrets, know-how, formulae, ideas, concepts, discoveries,
innovations, improvements, results, reports, information and data,
research, laboratory and programmer notebooks, methods, procedures,
proprietary technology, operating and maintenance manuals,
engineering and other drawings and sketches, customer lists,
supplier lists, pricing information, cost information, business
manufacturing and production processes and techniques, designs,
specifications, and blueprints (collectively, “Trade
Secrets”); and (5) all other intellectual property and
proprietary rights in any form or medium known or later devised,
all copies and tangible embodiments of the foregoing, and all
goodwill associated with any of the foregoing; and (6) the right to
bring suit, the right to claim and retain all damages and/or seek
other remedies for the past, present, and future infringement
and/or misappropriation of and the right to collect royalties and
other payments under or on account of any of the foregoing; in each
case whether registered or unregistered.

 

U.S.
patents and patent applications within the Gem Contributed
Intellectual Property:

 

1.            

[***].

2.            

[***].

3.            

[***].

4.            

[***].

5.            

[***].

6.            

[***].

7.            

[***].

8.            

Patent pending
[***], filed [***]: covers the composition of [***] and the
[***].

9.            

[***]

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

Foreign
patents and patent applications within the within the Gem
Contributed Intellectual Property:

 

	

Country

	

Patent
#

	

Based
on U.S. Patent No.

	
 [***]

	
 [***]

	
 [***]

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

	

	

	

 

	
 [***]

	

[***]

	

[***]

 

    Copyrights
and Trade Secrets within the Gem Contributed Intellectual
Property:

 

1.            

Analysis of [***]
for GPX-150

2.            

Analysis of
[***]for GPX-150

3.            

Analysis of [***]
for GPX-100

 

           Unpatented
inventions within the Gem Contributed Intellectual
Property:

 

           1.
GPX-160, GPX-170 and GPX-180

 

           Trademarks
within the Gem Contributed Intellectual Property:

 

          
1.            Gem
Pharmaceuticals (unregistered

2.           
On [***], Gem submitted an International Non-Proprietary Name
(INN)request to the World Health Organization for GPX-150, 
[***]

 

I.            

Gem
Contracts

 

License
Agreements (no active license agreements)

 

1.            

Non-binding term
sheet with Vitel Laboratories, expired on August 1,
2017.

2.            

Coronado
Biosciences agreement, expired on October 8, 2010.

3.            

[AOI, expired on
February 5, 2003]

 

Assigned
Research and Collaboration Agreements (no active agreements other
than [***])

 

1.
[***]:

-- two
Service Agreements, each expired April 30, 2016; fully completed
and fully paid

--
Service Agreement expired August 14, 2017; work complete but final
report due to be delivered soon after Closing. Gem agrees to
promptly deliver to Monopar said report upon receipt, to pay in
full all amounts owed under said Agreement, and if requested, to
use reasonable good faith efforts to obtain a consent from BSU in
substantially the same form as Exhibit E to the Contribution
Agreement.

 

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

--Service
Agreement expiring August 31, 2017; work complete and final report
has been delivered. Gem agrees to pay in full all amounts owed
under said Agreement.

2.
[***], expired on June 24, 2015.

3.
Agreements with [***] as reflected in proposals of [***] dated
April 21, 2016, June 24, 2016, July 5, 2016, and December 6,
2016.

Assigned
Manufacturing, Clinical Research and Compound Storage
Agreements

1.            

Manufacturing (All
manufacturing agreements other than [***] have
expired)

 

a.            

Tetrionics, expired
January, 2005.

b.            

SAFC, expired
August, 2015.

c.            

[***], dated May
31, 2017.

d.            

Bioserv, expired
January, 2016.

 

2.            

Clinical Research
Organizations (no active agreements)

 

a.            

Premier Research ,
expired on May 14, 2014.

b.            

Clinical Trial Data
Services, expired on March 26, 2017.

 

3.            

Compound
Storage

a.            

Clinical Supplies
Management, Inc., dated October 16, 2014.

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

Other
Gem Contracts

 

1.            

Renewal Service
Agreement between Gem Pharmaceuticals, LLC and CPAGlobaldated
August 31, 2016.

 

J.            

All inventory of
product, including raw materials, work in process and finished
product

 

1.            

Inventory of
GPX-150 and GPX-100 located in [***]

●            

200 vials of
GPX-150 product (about 50 mg/vial = about 10 grams of GPX-150 mixed
with lactose)

●            

6.8 grams of
GPX-150 from a batch made in 2006

2.            

Inventory of
clinical-grade GPX-150 located at CSM in [***]

●            

GPX-150 Powder
14.11 grams – expired 17 Nov 2016

●            

GPX-150 50mg vial
406 vials – expired 31 Oct 2016

3.            

Inventory of
GPX-150 (approximately 15 grams) located at [***]

 

 

 

 

 

EXHIBIT
B

 

Assigned
Contracts

 

 

1.
Master Services Agreement by and between Gem and Clinical Supplies
Management, Inc., dated October 1, 2014

 

2.
Renewal Service Agreement between Gem Pharmaceuticals, LLC and CPA
Global dated August 31, 2016

 

 

 

 

EXHIBIT
C

 

Form of
Consulting Agreement

 

See
attached.

 

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

CONSULTING AGREEMENT

 

This
Consulting Agreement (herein referred to as “Agreement”) is made and entered
into as of this day of , 2017 (the “Effective Date”), by and between
Monopar Therapeutics, Inc. (herein referred to as
“Monopar”), a
Delaware corporation, located at 5 Revere Dr., Suite 200,
Northbrook, IL 60062, and Gerald M. Walsh (herein referred to as
“Jerry”) who
resides at [***] (each herein referred
to as “Party” and collectively as
“Parties”).

 

RECITALS

 

WHEREAS, Jerry
specializes in the fields of pharmacology, toxicology, intellectual
property, and pharmaceutical management.

 

WHEREAS, Monopar
desires to contract with Jerry to provide certain consultation
services, as requested by Monopar, and Jerry wishes to provide such
services to Monopar, upon the terms and conditions set forth
below.

 

NOW,
THEREFORE, in consideration of the premises and mutual covenants
contained herein, the Parties agree as follows:

 

1. 

Consulting Arrangement. Jerry
agrees to perform consulting services as described herein upon the
terms and conditions herein set forth.

 

2.

Term of Agreement. Subject to
the provision for early termination set forth below in Section 5 of this Agreement, this
Agreement shall commence as of the Effective Date and shall
continue from the Effective Date through one year later (the “Term”).

 

3.

Duties of Jerry.

 

3.1 

Specific Duties. Jerry shall
provide consulting services to Monopar, such duties to include: See
Appendix A (herein referred to as the “Services”).

 

3.2 

Obligations. Jerry shall be
diligent in the performance of Services, and be professional in his
commitment to meeting his obligations hereunder. Jerry represents
and warrants that he is not party to any other existing agreement,
which would prevent him from entering into this Agreement or which
would adversely affect this Agreement. Jerry may be engaged or
employed in any other business, profession, or other activity but
Jerry shall not perform Services for any other individuals or
entities in direct competition with Monopar, within the scope of
Services under this Agreement, during the Term of this Agreement,
and for two years after its termination, except as provided for by
mutual written agreement of the Parties. Jerry shall not perform
services for any party which would require or facilitate the
unauthorized disclosure of any confidential or proprietary
information of Monopar.

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

3.3 

Reporting. Jerry will report to
Andrew P. Mazar, Ph.D. and liase with Chandler Robinson, M.D.,
Patrice Rioux, M.D. and/or any other assigned Monopar employee or
consultant as may be designated in writing by Monopar.

 

3.4            

Compensation. Monopar shall pay
Jerry as follows:

 

a.
[***] per month payable within thirty (30) days of the end of each
month.

 

b.
[***] per hour for consulting work that exceeds fifteen (15) hours
per month, and has been approved by Monopar. Jerry will document
all hours, including the initial fifteen (15) hours, and invoice
Monopar monthly for the hours above the first fifteen (15)
hours.

 

Jerry
shall not be reimbursed, and is responsible for the facilities
and equipment necessary to perform Services required under
this Agreement.

 

4.

Reimbursement of Expenses.
Monopar shall promptly reimburse Jerry for all direct expenses
incurred in providing the Services to Monopar pursuant to this
Agreement, including travel, meals and lodging as long as
Monopar’s prior approval has been obtained. Invoices
submitted by Jerry pursuant to this Section 4 shall also include a detail of
all reimbursable expenses incurred during the period covered by
such invoice as well as receipts. Per diem for food will be
reimbursed as per IRS specified rates in effect at that
time.

 

5.

Termination of Agreement - Failure to
perform. In the event that Jerry ceases to perform the
Services or breaches his obligations as required hereunder for any
reason and such cessation or breach remains uncured for ten (10)
business days following Monopar’s written notice thereof to
Jerry, Monopar shall have the right to immediately terminate this
Agreement upon notice to Jerry and to enforce such other rights and
remedies under this Agreement as it may have as a result of said
breach.

 

In the
event that Monopar breaches its obligations under this Agreement
and such breach remains uncured for ten (10) business days
following Jerry’s written notice thereof to Monopar, Jerry
shall have the right to immediately terminate this Agreement upon
notice to Monopar and to enforce such other rights and remedies
under this Agreement as it may have as a result of said
breach.

 

 

 

6.

Certain Liabilities. It is
understood and agreed that Jerry shall be acting as an independent
contractor and not as an agent or employee of, or partner, joint
venturer or in any other relationship with Monopar. Jerry will be
solely responsible for all insurance, employment taxes, FICA taxes
and all obligations to governments or other organizations for its
employees arising out of this consulting assignment. Jerry
acknowledges that no income, social security or other taxes shall
be withheld or accrued by Monopar for Jerry’s benefit. Jerry
assumes all risks and hazards encountered in the performance of
duties under this Agreement. Unless Monopar has provided prior
written approval, Jerry shall not use any sub-contractors to
perform obligations hereunder. Jerry shall be solely responsible
for any and all injuries, including death, to all persons and any
and all loss or damage to property, which may result from
performance under this Agreement.

 

 

 

7.

Indemnities. Jerry hereby
agrees to indemnify Monopar and hold Monopar harmless from and
against all claims (whether asserted by a person, firm, entity or
governmental unit or otherwise), liabilities, losses, damages,
expenses, charges and fees which Monopar may sustain or incur
arising out of or attributable to any gross negligence or willful
misconduct by Jerry, as applicable, in the performance under this
Agreement. Monopar hereby agrees to indemnify Jerry and hold Jerry
harmless from and against all liabilities, losses, damages,
expenses, charges and fees which Jerry may sustain or incur by
reason of any claim which may be asserted against Jerry by any
person, firm, corporation or governmental unit and which may arise
out of or be attributable to any gross negligence or willful
misconduct by Monopar or its employees or contractors, as
applicable, in the performance of this Agreement.

 

8.

Warranties. The Services shall
be performed in a professional manner, consistent with industry
standards. In performing the Services under this Agreement, Jerry
shall not make any unauthorized use of any confidential or
proprietary information of any other party or infringe the
intellectual property rights of any other party. Monopar represents
and warrants that it has full right, power, and authority to enter
into this Agreement and to perform its obligations
hereunder.

 

9.

Arbitration. Any controversy or
claim between Monopar and Jerry arising out of or relating to this
Agreement, or the breach thereof, shall be submitted to arbitration
in accordance with the rules of the American Arbitration
Association. The site of the arbitration shall be Chicago, IL, and
except as provided herein the arbitration shall be conducted in
accordance with the Rules of the American Arbitration Association
prevailing at the time the demand for arbitration is made
hereunder. At least one member of the arbitration panel shall be a
financial expert knowledgeable in the area of biopharmaceutical
corporate compliance. Judgment upon any award rendered by the
arbitrator(s) may be entered in any court of competent jurisdiction
and shall be binding and final. The cost of arbitration shall be
borne by the losing Party, as determined by the
arbitrator(s).

 

10.

Confidential Information. Jerry
has executed the attached confidential disclosure agreement
referenced herein as Appendix
B prior to commencement of the Services. Jerry hereby
represents and warrants that the obligations thereunder shall be
binding.

 

11. 

Inventions. Jerry agrees that
all ideas, developments, suggestions and inventions conceived or
reduced to practice, as a result of Services provided by Jerry
under this Agreement, shall be the exclusive property of Monopar
and shall be promptly communicated and assigned to Monopar. Jerry
shall require any other parties contracted by Jerry to disclose the
same to Jerry and to be bound by the provisions of this paragraph.
During the period of this Agreement and thereafter at any
reasonable time when called upon to do so by Monopar, Jerry shall
require any employees of or other parties contracted by Jerry to
execute patent applications, assignments to Monopar (or any
designee of Monopar) and other papers and to perform acts which
Monopar believes necessary to secure to Monopar full protection and
ownership of the rights in and to the services performed by Jerry
and/or for the preparation, filing and prosecution of applications
for patents or inventions made by any employees of or other parties
contracted by Jerry hereunder. The decision to file patent
applications on inventions made by any employees of or other
parties contracted by Jerry shall be made by Monopar and shall be
for such countries, as Monopar shall elect. Monopar agrees to bear
all the expense in connection with the preparation, filing and
prosecution of applications for patents and for all matters
provided in this paragraph requiring the time and/or assistance of
Jerry as to such inventions. Notwithstanding the foregoing, ideas,
developments, suggestions, and inventions conceived or reduced to
practice by Jerry that do not directly arise from Jerry’s
performance under this Agreement, shall be owned by
Jerry.

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

12. 

Miscellaneous.

 

12.1 

Notice. Any notices to be given
hereunder by either Party to the other may be effectuated, in
writing, by personal delivery, by electronic mail, or by mail,
registered or certified, postage prepaid, with return receipt
requested or by Federal Express. Mailed notices shall be addressed
to the parties at the following addresses:

 

If to
Monopar:                                   
Monopar Therapeutics, Inc

5
Revere Dr.

Suite
200

           

Northbrook, IL,
60062

Attention: Chandler
Robinson, M.D.

Email:
[***]

 

 

If to
Jerry:                                                      

Gerald
M.Walsh

           
           
           
           
           
           
    [***]

 

or at
such other addresses as either Monopar or Jerry may designate by
written notice to each other. Notices delivered personally shall be
deemed duly given on the date of actual receipt, mailed notices
shall be deemed duly given as of the fourth day after the date so
mailed, and electronic mail shall be deemed duly given upon
confirmation of receipt by recipient.

 

12.2 

Waiver of Breach. The waiver by
either Party to a breach of any provision in this Agreement cannot
operate or be construed as a waiver of any subsequent breach by
either Party.

 

12.3 

Severability. If any provision
of this Agreement is determined by a court of competent
jurisdiction to be invalid or unenforceable, that provision shall
be deemed modified to the extent necessary to make it valid or
enforceable, or if it cannot be so modified, then severed, and the
remainder of the Agreement shall continue in full force and effect
as if the Agreement had been signed with the invalid portion so
modified or severed.

 

 

 

12.4 

Choice of Law. This Agreement
has been made and entered into in the State of Illinois, and the
laws of such state, excluding its choice of law rules, shall govern the validity and
interpretation of this Agreement and the performance due hereunder.
The losing party in any dispute hereunder shall pay the
attorneys’ fees and disbursements of the prevailing
party.

 

12.5 

Integration. The drafting,
execution and delivery of this Agreement by the Parties have been
induced by no representations, statements, warranties or agreements
other than those expressed herein. This Agreement embodies the
entire understanding of the Parties, and there are no further or
other agreements or understandings, written or oral, in effect
between the Parties relating to the subject matter hereof unless
expressly referred to herein.

 

12.6 

Modification. This Agreement
may not be modified unless such is in writing and signed by both
Parties to this Agreement.

 

12.7 

Assignment. Jerry shall not be
permitted to assign this Agreement to any other person or entity
without the prior written consent of Monopar. Jerry hereby agrees
that Monopar shall be permitted to assign this Agreement to any
affiliate of Monopar. This Agreement shall be binding upon and
shall inure to the benefit of the successors and permitted assigns
of the parties.

 

12.8 

Survival. The provisions of
Sections 7, 8, 9, 10, and
11 shall survive expiration
or termination of this Agreement for any reason. Expiration or
termination of this Agreement shall not affect Monopar’s
obligations to pay any amounts that may then be due to
Jerry.

 

12.9 

Force Majeure. If Jerry’s
performance of his obligations under this Agreement is prevented or
delayed due to a flood, earthquake, war, terrorist act, revolution,
riot, or insurrection, Jerry shall not be deemed in breach of his
obligations under this Agreement or otherwise liable for any costs,
charges or losses sustained or incurred by Monopar, to the extent
arising directly from such force majeure event.

 

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement as
of the day and year first above written.

 

ACCEPTED
AND AGREED TO:

 

	

Gerald
M. Walsh

 

	
 

	

Monopar Therapeutics Inc

 

	
 

	
 

	
 

	

By: Individual

 

 

	
 

	

By: Chandler Robinson

 

Its: Chief Executive Officer

 

 

 

 

APPENDIX A

 

Services
include, but are not limited to, assisting the Monopar Management
team with the following:

 

1.            

Near and long term
planning of product development for existing Monopar drugs such as
Validive, ATN-658, GPX-150, GPX-160, GPX-170, and
GPX-180.

 

2.            

Developing near and
long term budgets for product development programs: preclicnal,
clinical, manufacturing, and related regulatory
affairs.

 

3.            

Designing,
managing, evaluating, and reporting for preclinical and clinical
studies and for manufacturing API and drug product.

 

4.            

Data storage and
retrieval for preclinical, clinical, manufacturing, and regulatory
programs.

 

5.            

Identifying and
evaluating suitable in-licensing drug products, including
evaluation of strength and scope of patent protection.

 

6.            

Identifying
patentable IP based on data from Monopar’s preclinical,
clinical, and manufacturing programs.

 

7.            

Creating
presentation content for Board Meetings, fund raising, and M&A
activities.

 

8.            

Evaluating
qualifications of employment candidates for Monopar.

 

9.            

Any other Services
required by Monopar.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Appendix
B

 

 

See
executed CDA attached

 

  

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

 

 

MONOPAR THERAPEUTICS INC.

CONFIDENTIAL DISCLOSURE AGREEMENT

 

AGREEMENT
between the individual Gerald M. Walsh (“Recipient”)
and Monopar Therapeutics Inc.
(“Monopar”).

 

 

In
consideration for the mutual agreements contained herein and the
other provisions of this Agreement, the receipt of which is hereby
acknowledged by the parties, the parties hereto agree as
follows:

 

1. Scope of Confidential Information

 

“Confidential
Information” means, subject to the other provisions of this
Section:

 

(a) all
information, whether oral or written, disclosed by Monopar that is
described in Schedule A under “Description of Confidential
Information”. Confidential Information may relate to the
activities or property of Monopar or any of Monopar’s
members, directors, officers, employees, consultants, agents,
representatives or affiliated entities (collectively,
“Associated Persons”); and

 

(b) any
written material prepared by Recipient or Recipient’s
partners, directors, officers, employees, agents, representatives
or affiliated entities (collectively, “Associated
Persons”) containing any Monopar Confidential
Information.

 

“Confidential
Information” does not include information that: (i) was
available to Recipient (free of any confidentiality obligation in
favor of Monopar) prior to disclosure of such information by
Monopar to Recipient; (ii) is made available to Recipient from a
third party which (at the time of such availability) was not, to
Recipient’s knowledge, subject to a confidentiality
obligation with respect to such information; (iii) is made
available to third parties by Monopar without restriction on the
disclosure of such information, (iv) is or becomes available to the
public on or after the date of this Agreement (other than as a
result of disclosure prohibited by any confidentiality obligation
contained herein); or (v) is developed independently by Recipient
or its Associated Persons without reference to the Confidential
Information.

 

Recipient
agrees that it will not disclose to Monopar or to any of its
employees or consultants any confidential, proprietary, or trade
secret information, or any other form of confidential protectable
intellectual property, regardless of whether such information is
the property of Recipient itself or of some other individual or
organization.

 

2. Use and Disclosure of Confidential Information

 

(a)
Recipient agrees: (i) to preserve the confidentiality of
Confidential Information for [***] from the date of signing this
Agreement; (ii) to use and/or permit the use of Confidential
Information only for the purposes of, and to the extent necessary
for, evaluating a business relationship between the parties and, if
such a relationship is consummated, carrying out such relationship;
(iii) to disclose Confidential Information to, and to permit the
use of Confidential Information by, only such persons within
Recipient who Recipient reasonably determines need to know such
information in connection with the activities described in (ii)
above; and (iv) to use reasonable care to maintain the
confidentiality of Confidential Information, provided that such
care shall be at least as great as the precautions taken by
Recipient to protect its own confidential and/or proprietary
information.

 

(b)
Notwithstanding anything to the contrary herein, Recipient is free
to make (and this Agreement does not restrict) disclosure of any
Confidential Information in a judicial, legislative, or
administrative investigation or proceeding or to a government or
other regulatory agency; provided that, to the extent permitted by,
and practicable under, the circumstances, Recipient provides to
Monopar (i) prior notice of the intended disclosure or (ii) if
prior notice is not permitted or practicable under the
circumstances, prompt notice of such disclosure.

 

3. Certain Rights and Limitations

 

(a) All
Confidential Information shall remain the property of Monopar. The
provision of Confidential Information hereunder shall not transfer
any right, title or interest in such information to Recipient.
Monopar does not grant any express or implied right to Recipient to
or under Monopar’s patents, copyrights, trademarks, trade
secret information or other proprietary rights.

 

(b)
Recipient agrees to adhere to all applicable laws and regulations
relating to the export of technical data received
hereunder.

 

(c)
This Agreement imposes no obligations on either party to purchase,
sell, license, transfer or otherwise transact in any technology,
services or products. This Agreement does not create any agency or
partnership relationship between the parties hereto.

 

(d) All
information disclosed hereunder is without representation or
warranty of any kind whatsoever, including without limitation, any
representation or warranty as to accuracy or completeness, whether
express or implied.

 

4. Remedies

 

(a)
Upon Monopar’s reasonable request, Recipient agrees to return
promptly to Monopar all Confidential Information that is in writing
and in the possession of Recipient and, upon written request, to
certify the return or destruction (at Monopar’s option) of
all Confidential Information.

 

(b)
Recipient agrees that monetary damages may not be an adequate
remedy for improper disclosure or use of Confidential Information,
that Monopar, upon breach of this contract, shall be entitled to
such injunctive or equitable relief as may be deemed proper by a
court of competent jurisdiction, without waiving any other right or
remedy, and that Recipient shall not resist an application for such
relief on the ground that Monopar has an adequate remedy at
law.

 

5. Miscellaneous

 

 (a)
Except where expressly indicated otherwise, the words
“written” or “in writing” shall include,
but not be limited to, written or printed documents, electronic and
facsimile transmissions and computer disks or tapes (whether
machine or user readable).

 

(b) In
the event that any one or more of the provisions of this Agreement
will for any reason be held to be invalid, illegal or unenforceable
by a court of competent jurisdiction, the remaining provisions of
this Agreement will be unimpaired, and the invalid, illegal or
unenforceable provisions will be replaced by a mutually acceptable
provision, which being valid, legal or enforceable, comes closest
to the intention of the parties underlying the invalid, illegal or
unenforceable provision.

 

(c) No
amendment or alteration of the terms of this Agreement shall be
effective unless made in writing and executed by both parties
hereto.

 

(d) A
failure or delay in exercising any right in respect of this
Agreement will not be presumed to operate as a waiver, and a single
or partial exercise of any right will not be presumed to preclude
any subsequent or further exercise of that right or the exercise of
any other right. Any modification or waiver of any provision of
this Agreement shall not be effective unless made in writing. Any
such waiver shall be effective only in the specific instance and
for the purpose given.

 

(e)
This Agreement and its enforcement
shall be governed by, and construed in accordance with, the laws of
the State of Illinois, without regard to conflicts-of-law
principles.

 

 

 

 

[***] = Confidential Information has
been omitted and filed separately with the Securities and Exchange
Commission. 

Confidential
treatment has been requested with respect to the omitted
information.

[SIGNATURE PAGE
FOLLOWS]

 

 

 

IN
WITNESS WHEREOF, the parties hereto have executed this
Agreement.

 

 

 

	

“RECIPIENT”

 

 

 

 

By:_______________________________________

Name:
Gerald M. Walsh

Title:
Consultant

 

 

Date:_____________________________________

 

Notices
hereunder shall be sent to:

Gerald
M. Walsh

[***]

 

 

	

“MONOPAR”

 

Monopar
Therapeutics Inc.

 

 

By:_______________________________________

Name:
Chandler D. Robinson

 Title:
CEO

 

 

Date:
_____________________________________

 

Notices
hereunder shall be sent to:

 

[***]

 

 

 

 

	
 

	
 

SCHEDULE A

 

Description
of Confidential Information Disclosed by Monopar:

 

(a) The
identity of the particular compound or compounds under
investigation by Monopar; (b) the medical indication and/or other
purpose for which any of these compounds are being investigated by
Monopar; (c) the (known or putative) mechanism of action of any of
these compounds; (d) any techniques used by Monopar to discover,
develop, produce, or test any of these compounds; and (e) any
non-public business, financial, regulatory, clinical or scientific
information pertaining to Monopar or the compound or compounds that
Monopar identifies as confidential when disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]